EP4337259A1 - Composés pour la dégradation d'agrégats d'alpha-synucléine et leurs utilisations - Google Patents
Composés pour la dégradation d'agrégats d'alpha-synucléine et leurs utilisationsInfo
- Publication number
- EP4337259A1 EP4337259A1 EP21726997.6A EP21726997A EP4337259A1 EP 4337259 A1 EP4337259 A1 EP 4337259A1 EP 21726997 A EP21726997 A EP 21726997A EP 4337259 A1 EP4337259 A1 EP 4337259A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- formula
- alkyl
- substituted
- compound
- unsubstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 601
- 108090000185 alpha-Synuclein Proteins 0.000 title abstract description 5
- 102000003802 alpha-Synuclein Human genes 0.000 title abstract 2
- 230000000593 degrading effect Effects 0.000 title description 5
- 230000027455 binding Effects 0.000 claims abstract description 32
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 claims abstract description 20
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 claims abstract description 20
- 208000032859 Synucleinopathies Diseases 0.000 claims abstract description 19
- 125000000217 alkyl group Chemical group 0.000 claims description 216
- 229910052760 oxygen Inorganic materials 0.000 claims description 200
- 229910052739 hydrogen Inorganic materials 0.000 claims description 189
- 238000000034 method Methods 0.000 claims description 168
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 164
- 229910052757 nitrogen Inorganic materials 0.000 claims description 147
- 125000005842 heteroatom Chemical group 0.000 claims description 145
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 141
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims description 137
- 229910052736 halogen Inorganic materials 0.000 claims description 136
- 150000002367 halogens Chemical class 0.000 claims description 136
- 229910052717 sulfur Inorganic materials 0.000 claims description 134
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 119
- 150000002430 hydrocarbons Chemical group 0.000 claims description 115
- 125000003545 alkoxy group Chemical group 0.000 claims description 114
- -1 n-propylene Chemical group 0.000 claims description 104
- 125000003118 aryl group Chemical group 0.000 claims description 96
- 125000005843 halogen group Chemical group 0.000 claims description 89
- 150000003839 salts Chemical class 0.000 claims description 85
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims description 84
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims description 79
- 239000012453 solvate Substances 0.000 claims description 79
- 229940002612 prodrug Drugs 0.000 claims description 75
- 239000000651 prodrug Substances 0.000 claims description 75
- 230000002503 metabolic effect Effects 0.000 claims description 74
- 239000002243 precursor Substances 0.000 claims description 74
- 125000006310 cycloalkyl amino group Chemical group 0.000 claims description 71
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 68
- 125000004429 atom Chemical group 0.000 claims description 63
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 61
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 60
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 60
- 239000001257 hydrogen Substances 0.000 claims description 59
- 125000002950 monocyclic group Chemical group 0.000 claims description 59
- 229910052799 carbon Inorganic materials 0.000 claims description 58
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims description 54
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 51
- 125000003282 alkyl amino group Chemical group 0.000 claims description 48
- 125000001188 haloalkyl group Chemical group 0.000 claims description 44
- 229910052770 Uranium Inorganic materials 0.000 claims description 39
- 125000002619 bicyclic group Chemical group 0.000 claims description 36
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 31
- 125000006317 cyclopropyl amino group Chemical group 0.000 claims description 30
- 125000002252 acyl group Chemical group 0.000 claims description 27
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 26
- 125000004122 cyclic group Chemical group 0.000 claims description 23
- 125000005647 linker group Chemical group 0.000 claims description 23
- 108090000623 proteins and genes Proteins 0.000 claims description 22
- 102000004169 proteins and genes Human genes 0.000 claims description 22
- 208000018737 Parkinson disease Diseases 0.000 claims description 21
- 210000004558 lewy body Anatomy 0.000 claims description 21
- 201000002832 Lewy body dementia Diseases 0.000 claims description 16
- 230000002776 aggregation Effects 0.000 claims description 16
- 238000004220 aggregation Methods 0.000 claims description 16
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 15
- 125000002947 alkylene group Chemical group 0.000 claims description 15
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims description 14
- 125000004474 heteroalkylene group Chemical group 0.000 claims description 12
- 125000000623 heterocyclic group Chemical group 0.000 claims description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 11
- 239000001301 oxygen Chemical group 0.000 claims description 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 125000005549 heteroarylene group Chemical group 0.000 claims description 10
- 125000004419 alkynylene group Chemical group 0.000 claims description 9
- 125000004450 alkenylene group Chemical group 0.000 claims description 8
- 125000000732 arylene group Chemical group 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 6
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical group C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 6
- 229910052720 vanadium Inorganic materials 0.000 claims description 6
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical group CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 claims description 5
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 claims description 5
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 5
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 claims description 4
- PUJDIJCNWFYVJX-UHFFFAOYSA-N benzyl carbamate Chemical compound NC(=O)OCC1=CC=CC=C1 PUJDIJCNWFYVJX-UHFFFAOYSA-N 0.000 claims description 4
- FGIVSGPRGVABAB-UHFFFAOYSA-N fluoren-9-ylmethyl hydrogen carbonate Chemical compound C1=CC=C2C(COC(=O)O)C3=CC=CC=C3C2=C1 FGIVSGPRGVABAB-UHFFFAOYSA-N 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 125000003386 piperidinyl group Chemical group 0.000 claims description 4
- XKXIQBVKMABYQJ-UHFFFAOYSA-M tert-butyl carbonate Chemical compound CC(C)(C)OC([O-])=O XKXIQBVKMABYQJ-UHFFFAOYSA-M 0.000 claims description 4
- LMYRWZFENFIFIT-UHFFFAOYSA-N toluene-4-sulfonamide Chemical compound CC1=CC=C(S(N)(=O)=O)C=C1 LMYRWZFENFIFIT-UHFFFAOYSA-N 0.000 claims description 4
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 claims description 3
- 125000006591 (C2-C6) alkynylene group Chemical group 0.000 claims description 3
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 3
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 3
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- 238000011282 treatment Methods 0.000 abstract description 25
- 208000015122 neurodegenerative disease Diseases 0.000 abstract description 6
- 230000004770 neurodegeneration Effects 0.000 abstract description 5
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 327
- 239000000203 mixture Substances 0.000 description 185
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 165
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 156
- YMWUJEATGCHHMB-UHFFFAOYSA-N dichloromethane Natural products ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 155
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 124
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 123
- 239000000243 solution Substances 0.000 description 107
- 239000007787 solid Substances 0.000 description 102
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 96
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 96
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 82
- 238000004440 column chromatography Methods 0.000 description 70
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 67
- 239000012267 brine Substances 0.000 description 67
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 67
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 65
- 239000012044 organic layer Substances 0.000 description 57
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 56
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 56
- 229910052731 fluorine Inorganic materials 0.000 description 55
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 description 55
- 235000019439 ethyl acetate Nutrition 0.000 description 48
- 230000015572 biosynthetic process Effects 0.000 description 37
- 238000003786 synthesis reaction Methods 0.000 description 37
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 34
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 32
- 125000005825 oxyethoxy group Chemical group [H]C([H])(O[*:1])C([H])([H])O[*:2] 0.000 description 30
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 28
- VRZVPALEJCLXPR-UHFFFAOYSA-N ethyl 4-methylbenzenesulfonate Chemical compound CCOS(=O)(=O)C1=CC=C(C)C=C1 VRZVPALEJCLXPR-UHFFFAOYSA-N 0.000 description 27
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 24
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 23
- PCBZRNYXXCIELG-WYFCWLEVSA-N COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 Chemical compound COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 PCBZRNYXXCIELG-WYFCWLEVSA-N 0.000 description 22
- 201000010099 disease Diseases 0.000 description 22
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 21
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 20
- 238000001914 filtration Methods 0.000 description 20
- 239000011541 reaction mixture Substances 0.000 description 20
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 19
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 16
- 229910000027 potassium carbonate Inorganic materials 0.000 description 16
- 235000015320 potassium carbonate Nutrition 0.000 description 16
- 230000001575 pathological effect Effects 0.000 description 15
- 239000000741 silica gel Substances 0.000 description 15
- 229910002027 silica gel Inorganic materials 0.000 description 15
- 229910052721 tungsten Inorganic materials 0.000 description 15
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- 239000008194 pharmaceutical composition Substances 0.000 description 14
- 125000004432 carbon atom Chemical group C* 0.000 description 13
- KNCYXPMJDCCGSJ-UHFFFAOYSA-N piperidine-2,6-dione Chemical compound O=C1CCCC(=O)N1 KNCYXPMJDCCGSJ-UHFFFAOYSA-N 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 13
- 125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 210000004556 brain Anatomy 0.000 description 12
- 239000003921 oil Substances 0.000 description 12
- 235000019198 oils Nutrition 0.000 description 12
- 239000002244 precipitate Substances 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- VYVPNTJBGPQTFA-UHFFFAOYSA-N 2-[2-(4-methylphenyl)sulfonyloxyethoxy]ethyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCCOCCOS(=O)(=O)C1=CC=C(C)C=C1 VYVPNTJBGPQTFA-UHFFFAOYSA-N 0.000 description 10
- 238000001556 precipitation Methods 0.000 description 10
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 8
- LVQFHDAKZHGEAJ-UHFFFAOYSA-M 4-methylbenzenesulfonate Chemical compound [CH2]C1=CC=C(S([O-])(=O)=O)C=C1 LVQFHDAKZHGEAJ-UHFFFAOYSA-M 0.000 description 7
- 102100026882 Alpha-synuclein Human genes 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 7
- 239000000460 chlorine Substances 0.000 description 7
- 238000004587 chromatography analysis Methods 0.000 description 7
- 125000003709 fluoroalkyl group Chemical group 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 125000001424 substituent group Chemical group 0.000 description 7
- 239000011593 sulfur Chemical group 0.000 description 7
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 7
- JJUMFQGCQAUIFH-UHFFFAOYSA-N 3-(6-hydroxy-3-oxo-1h-isoindol-2-yl)piperidine-2,6-dione Chemical compound C1C2=CC(O)=CC=C2C(=O)N1C1CCC(=O)NC1=O JJUMFQGCQAUIFH-UHFFFAOYSA-N 0.000 description 6
- YCPULGHBTPQLRH-UHFFFAOYSA-N 3-aminopiperidine-2,6-dione;hydron;chloride Chemical compound Cl.NC1CCC(=O)NC1=O YCPULGHBTPQLRH-UHFFFAOYSA-N 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 239000005457 ice water Substances 0.000 description 6
- 210000002569 neuron Anatomy 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 229940032147 starch Drugs 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 101000605835 Homo sapiens Serine/threonine-protein kinase PINK1, mitochondrial Proteins 0.000 description 5
- 102100032693 Leucine-rich repeat serine/threonine-protein kinase 2 Human genes 0.000 description 5
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 5
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 5
- 102100038376 Serine/threonine-protein kinase PINK1, mitochondrial Human genes 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 229910052801 chlorine Inorganic materials 0.000 description 5
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- ZIZXHPCBPDNLDD-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-(4-methylphenyl)sulfonyloxyethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCCOCCOCCOCCOCCOCCOS(=O)(=O)C1=CC=C(C)C=C1 ZIZXHPCBPDNLDD-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 description 4
- 101000619542 Homo sapiens E3 ubiquitin-protein ligase parkin Proteins 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- NZNMILVWEHOGBB-UHFFFAOYSA-N NC(C(CCC(=O)O)N1C(C2=CC=C(C=C2C1)O)=O)=O Chemical compound NC(C(CCC(=O)O)N1C(C2=CC=C(C=C2C1)O)=O)=O NZNMILVWEHOGBB-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- 235000011054 acetic acid Nutrition 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 229910052786 argon Inorganic materials 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 208000018637 late onset Parkinson disease Diseases 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 102000045222 parkin Human genes 0.000 description 4
- KOUCTZDKTJGHSS-UHFFFAOYSA-N pentyl 4-methylbenzenesulfonate Chemical compound CCCCCOS(=O)(=O)C1=CC=C(C)C=C1 KOUCTZDKTJGHSS-UHFFFAOYSA-N 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 3
- VPVJWIKIKYUVOX-UHFFFAOYSA-N 3-[2-[2-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]oxy]ethoxy]ethoxy]propanoic acid Chemical compound OC(CCOCCOCCOC(C=C1CN2C(CCC(N3)=O)C3=O)=CC=C1C2=O)=O VPVJWIKIKYUVOX-UHFFFAOYSA-N 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000887201 Homo sapiens Polyamine-transporting ATPase 13A2 Proteins 0.000 description 3
- 235000019502 Orange oil Nutrition 0.000 description 3
- 102100039917 Polyamine-transporting ATPase 13A2 Human genes 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000035508 accumulation Effects 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 230000008499 blood brain barrier function Effects 0.000 description 3
- 210000001218 blood-brain barrier Anatomy 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 238000012754 cardiac puncture Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000000105 evaporative light scattering detection Methods 0.000 description 3
- 150000004677 hydrates Chemical class 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 125000006574 non-aromatic ring group Chemical group 0.000 description 3
- 239000010502 orange oil Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- XASWYPVFCVEQSU-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;potassium Chemical compound [K].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O XASWYPVFCVEQSU-UHFFFAOYSA-N 0.000 description 2
- RNWRKOPOPSZBFZ-UHFFFAOYSA-N 2-[4-[6-[(2-methylpropan-2-yl)oxycarbonylamino]pyridin-3-yl]phenyl]pyrrolo[2,3-c]pyridine-1-carboxylic acid Chemical compound CC(C)(C)OC(NC(N=C1)=CC=C1C(C=C1)=CC=C1C1=CC2=CC=NC=C2N1C(O)=O)=O RNWRKOPOPSZBFZ-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- 241000272517 Anseriformes Species 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- LPICBHMSLLEAQL-UHFFFAOYSA-N CC1=CC=C(C=C1)S(=O)(=O)OCCOCCOCCOCCOCCO[Si](C)(C)C(C)(C)C Chemical compound CC1=CC=C(C=C1)S(=O)(=O)OCCOCCOCCOCCOCCO[Si](C)(C)C(C)(C)C LPICBHMSLLEAQL-UHFFFAOYSA-N 0.000 description 2
- VDWOJLHWBRGTHO-UHFFFAOYSA-N CN(C)C1=CC2=C(C=C1)N=C(S2)C3=CC=C(C=C3)C4=CN=C(C=C4)OC(=O)NCCOCCN5C(=O)CCC(C5=O)N6CC7=C(C6=O)C=CC(=C7)O Chemical compound CN(C)C1=CC2=C(C=C1)N=C(S2)C3=CC=C(C=C3)C4=CN=C(C=C4)OC(=O)NCCOCCN5C(=O)CCC(C5=O)N6CC7=C(C6=O)C=CC(=C7)O VDWOJLHWBRGTHO-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 229910052684 Cerium Inorganic materials 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- 102100039683 Cyclin-G-associated kinase Human genes 0.000 description 2
- 208000019505 Deglutition disease Diseases 0.000 description 2
- 102100027346 GTP cyclohydrolase 1 Human genes 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 101000862581 Homo sapiens GTP cyclohydrolase 1 Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 208000009829 Lewy Body Disease Diseases 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- 102100026918 Phospholipase A2 Human genes 0.000 description 2
- 101710096328 Phospholipase A2 Proteins 0.000 description 2
- 239000008156 Ringer's lactate solution Substances 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 230000006736 behavioral deficit Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052792 caesium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229940099112 cornstarch Drugs 0.000 description 2
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- JJXVDRYFBGDXOU-UHFFFAOYSA-N dimethyl 4-hydroxybenzene-1,2-dicarboxylate Chemical compound COC(=O)C1=CC=C(O)C=C1C(=O)OC JJXVDRYFBGDXOU-UHFFFAOYSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000003979 granulating agent Substances 0.000 description 2
- 238000003365 immunocytochemistry Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 125000000468 ketone group Chemical group 0.000 description 2
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 2
- FFQAITMDLOKTFE-UHFFFAOYSA-N methyl 5-amino-4-(6-hydroxy-3-oxo-1H-isoindol-2-yl)-5-oxopentanoate Chemical compound COC(CCC(C(N)=O)N(CC1=CC(O)=CC=C11)C1=O)=O FFQAITMDLOKTFE-UHFFFAOYSA-N 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 208000002593 pantothenate kinase-associated neurodegeneration Diseases 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000000946 synaptic effect Effects 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- UTQNKKSJPHTPBS-UHFFFAOYSA-N 2,2,2-trichloroethanone Chemical group ClC(Cl)(Cl)[C]=O UTQNKKSJPHTPBS-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
- KCONMNWPRXAWKK-UHFFFAOYSA-N 2-[2-[2-(4-methylphenyl)sulfonyloxyethoxy]ethoxy]ethyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCCOCCOCCOS(=O)(=O)C1=CC=C(C)C=C1 KCONMNWPRXAWKK-UHFFFAOYSA-N 0.000 description 1
- SLAONPBUWDUSSO-UHFFFAOYSA-N 2-[2-[2-[2-(4-methylphenyl)sulfonyloxyethoxy]ethoxy]ethoxy]ethyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCCOCCOCCOCCOS(=O)(=O)C1=CC=C(C)C=C1 SLAONPBUWDUSSO-UHFFFAOYSA-N 0.000 description 1
- OHANZAJUTVTYPD-UHFFFAOYSA-N 2-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]oxy]acetic acid Chemical compound OC(=O)COC1=CC2=C(C=C1)C(=O)N(C2)C1CCC(=O)NC1=O OHANZAJUTVTYPD-UHFFFAOYSA-N 0.000 description 1
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 1
- AWBYNTHBIFCMFC-UHFFFAOYSA-N 2-azidoethyl 4-methylbenzenesulfonate Chemical compound CC1=CC=C(S(=O)(=O)OCCN=[N+]=[N-])C=C1 AWBYNTHBIFCMFC-UHFFFAOYSA-N 0.000 description 1
- HGPRKOYQOBYISD-UHFFFAOYSA-N 3-(7-hydroxy-3-oxo-1h-isoindol-2-yl)piperidine-2,6-dione Chemical compound C1C=2C(O)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O HGPRKOYQOBYISD-UHFFFAOYSA-N 0.000 description 1
- YUNQZQREIHWDQT-UHFFFAOYSA-N 4-bromo-n-(6-methoxy-1,3-dimethyl-2-oxobenzimidazol-5-yl)-2-methylbenzenesulfonamide Chemical compound COC1=CC=2N(C)C(=O)N(C)C=2C=C1NS(=O)(=O)C1=CC=C(Br)C=C1C YUNQZQREIHWDQT-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- GMMNFKKJUMYAPM-UHFFFAOYSA-N 5-(4-methylphenyl)sulfonyloxypentyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCCCCCOS(=O)(=O)C1=CC=C(C)C=C1 GMMNFKKJUMYAPM-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 102100037991 85/88 kDa calcium-independent phospholipase A2 Human genes 0.000 description 1
- 102100029824 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 2 Human genes 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- 208000005685 Adult-onset dystonia-parkinsonism Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000007415 Anhedonia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010002942 Apathy Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- JOGMLVNCICWNMJ-UHFFFAOYSA-N CC(C)(C)C1=C(C(C=C2)=CC=C2C2=CC=C(N(CCOCCOCCOCCOCCOCCOS(C3=CC=C(C)C=C3)(=O)=O)C(OC(C)(C)C)=O)N=C2)NC2=CN=CC=C12 Chemical compound CC(C)(C)C1=C(C(C=C2)=CC=C2C2=CC=C(N(CCOCCOCCOCCOCCOCCOS(C3=CC=C(C)C=C3)(=O)=O)C(OC(C)(C)C)=O)N=C2)NC2=CN=CC=C12 JOGMLVNCICWNMJ-UHFFFAOYSA-N 0.000 description 1
- IAUKDSDESQCJHN-UHFFFAOYSA-N CC1=CC=C(C=C1)S(=O)(=O)OCCOCCOCCOCCOCCOCCOC=1C=CC=2N(C=1)C=C(N=2)C1=CC=C(C=C1)C=1C(=NC(=CC=1)N(C)C)F Chemical compound CC1=CC=C(C=C1)S(=O)(=O)OCCOCCOCCOCCOCCOCCOC=1C=CC=2N(C=1)C=C(N=2)C1=CC=C(C=C1)C=1C(=NC(=CC=1)N(C)C)F IAUKDSDESQCJHN-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 102100035180 Coiled-coil domain-containing protein 62 Human genes 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000012694 DDRGK1 Human genes 0.000 description 1
- 101150011286 DDRGK1 gene Proteins 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 102100030221 Diacylglycerol kinase theta Human genes 0.000 description 1
- 208000003164 Diplopia Diseases 0.000 description 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 101710199743 F-box only protein 7 Proteins 0.000 description 1
- 102100029525 F-box only protein 7 Human genes 0.000 description 1
- 208000034347 Faecal incontinence Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102100031361 Fibroblast growth factor 20 Human genes 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 102100027778 GTP-binding protein Rit2 Human genes 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 102100028640 HLA class II histocompatibility antigen, DR beta 5 chain Human genes 0.000 description 1
- 108010016996 HLA-DRB5 Chains Proteins 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 101001095960 Homo sapiens 85/88 kDa calcium-independent phospholipase A2 Proteins 0.000 description 1
- 101000794082 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 2 Proteins 0.000 description 1
- 101000737082 Homo sapiens Coiled-coil domain-containing protein 62 Proteins 0.000 description 1
- 101000886209 Homo sapiens Cyclin-G-associated kinase Proteins 0.000 description 1
- 101000864574 Homo sapiens Diacylglycerol kinase theta Proteins 0.000 description 1
- 101000846532 Homo sapiens Fibroblast growth factor 20 Proteins 0.000 description 1
- 101001099051 Homo sapiens GPI inositol-deacylase Proteins 0.000 description 1
- 101000725879 Homo sapiens GTP-binding protein Rit2 Proteins 0.000 description 1
- 101000941879 Homo sapiens Leucine-rich repeat serine/threonine-protein kinase 2 Proteins 0.000 description 1
- 101001056160 Homo sapiens Methylcrotonoyl-CoA carboxylase subunit alpha, mitochondrial Proteins 0.000 description 1
- 101000891579 Homo sapiens Microtubule-associated protein tau Proteins 0.000 description 1
- 101001137535 Homo sapiens Nuclear ubiquitous casein and cyclin-dependent kinase substrate 1 Proteins 0.000 description 1
- 101000869523 Homo sapiens Phosphatidylinositide phosphatase SAC2 Proteins 0.000 description 1
- 101000882219 Homo sapiens Protein FAM47E Proteins 0.000 description 1
- 101000712725 Homo sapiens Ras-related protein Rab-7L1 Proteins 0.000 description 1
- 101000835998 Homo sapiens SRA stem-loop-interacting RNA-binding protein, mitochondrial Proteins 0.000 description 1
- 101000701497 Homo sapiens STE20/SPS1-related proline-alanine-rich protein kinase Proteins 0.000 description 1
- 101000654500 Homo sapiens Signal-induced proliferation-associated 1-like protein 2 Proteins 0.000 description 1
- 101000626379 Homo sapiens Synaptotagmin-11 Proteins 0.000 description 1
- 101000585079 Homo sapiens Syntaxin-1B Proteins 0.000 description 1
- 101000904724 Homo sapiens Transmembrane glycoprotein NMB Proteins 0.000 description 1
- 101000667104 Homo sapiens Vacuolar protein sorting-associated protein 13C Proteins 0.000 description 1
- 101000854862 Homo sapiens Vacuolar protein sorting-associated protein 35 Proteins 0.000 description 1
- 101000739853 Homo sapiens [3-methyl-2-oxobutanoate dehydrogenase [lipoamide]] kinase, mitochondrial Proteins 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical group NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108010020246 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102100037611 Lysophospholipase Human genes 0.000 description 1
- 102100033342 Lysosomal acid glucosylceramidase Human genes 0.000 description 1
- 102100020983 Lysosome membrane protein 2 Human genes 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102100026552 Methylcrotonoyl-CoA carboxylase subunit alpha, mitochondrial Human genes 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102100040243 Microtubule-associated protein tau Human genes 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 229910003204 NH2 Inorganic materials 0.000 description 1
- 102100021007 Nuclear ubiquitous casein and cyclin-dependent kinase substrate 1 Human genes 0.000 description 1
- BURHAZLANYBZOZ-UHFFFAOYSA-N OC(=O)CCOCCOCCI Chemical compound OC(=O)CCOCCOCCI BURHAZLANYBZOZ-UHFFFAOYSA-N 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
- 102100032287 Phosphatidylinositide phosphatase SAC2 Human genes 0.000 description 1
- 108010058864 Phospholipases A2 Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100038928 Protein FAM47E Human genes 0.000 description 1
- 208000009144 Pure autonomic failure Diseases 0.000 description 1
- 208000025535 REM sleep behavior disease Diseases 0.000 description 1
- 102100033100 Ras-related protein Rab-7L1 Human genes 0.000 description 1
- 208000005793 Restless legs syndrome Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108091005488 SCARB2 Proteins 0.000 description 1
- 108091006983 SLC41A1 Proteins 0.000 description 1
- 101150110423 SNCA gene Proteins 0.000 description 1
- 102100025491 SRA stem-loop-interacting RNA-binding protein, mitochondrial Human genes 0.000 description 1
- 102100030491 STE20/SPS1-related proline-alanine-rich protein kinase Human genes 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 208000008630 Sialorrhea Diseases 0.000 description 1
- 102100031451 Signal-induced proliferation-associated 1-like protein 2 Human genes 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 102100032013 Solute carrier family 41 member 1 Human genes 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102000004874 Synaptophysin Human genes 0.000 description 1
- 108090001076 Synaptophysin Proteins 0.000 description 1
- 102100024609 Synaptotagmin-11 Human genes 0.000 description 1
- 102100029931 Syntaxin-1B Human genes 0.000 description 1
- 239000012317 TBTU Substances 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 102100039112 Vacuolar protein sorting-associated protein 13C Human genes 0.000 description 1
- 102100020822 Vacuolar protein sorting-associated protein 35 Human genes 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 102100037607 [3-methyl-2-oxobutanoate dehydrogenase [lipoamide]] kinase, mitochondrial Human genes 0.000 description 1
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 125000005101 aryl methoxy carbonyl group Chemical group 0.000 description 1
- 125000005002 aryl methyl group Chemical group 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 208000026030 autosomal recessive Parkinson disease 14 Diseases 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000004638 bioanalytical method Methods 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- BMLSTPRTEKLIPM-UHFFFAOYSA-I calcium;potassium;disodium;hydrogen carbonate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].OC([O-])=O BMLSTPRTEKLIPM-UHFFFAOYSA-I 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 229940023913 cation exchange resins Drugs 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229960005168 croscarmellose Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000002993 cycloalkylene group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- NLUNLVTVUDIHFE-UHFFFAOYSA-N cyclooctylcyclooctane Chemical compound C1CCCCCCC1C1CCCCCCC1 NLUNLVTVUDIHFE-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000008355 dextrose injection Substances 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000004582 dihydrobenzothienyl group Chemical group S1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000004655 dihydropyridinyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000000806 fluorine-19 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 210000005154 hemibrain Anatomy 0.000 description 1
- 125000006588 heterocycloalkylene group Chemical group 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 206010020765 hypersomnia Diseases 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- CUAUQBKUHAZSIJ-UHFFFAOYSA-N isoindole-1,3-dione Chemical compound C1=C=C[C]2C(=O)NC(=O)C2=C1 CUAUQBKUHAZSIJ-UHFFFAOYSA-N 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960004942 lenalidomide Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000012006 liquid chromatography with tandem mass spectrometry Methods 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 108091031561 miR-4697 stem-loop Proteins 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000006682 monohaloalkyl group Chemical group 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000005155 neural progenitor cell Anatomy 0.000 description 1
- 210000002241 neurite Anatomy 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 208000031237 olivopontocerebellar atrophy Diseases 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 125000005882 oxadiazolinyl group Chemical group 0.000 description 1
- 125000003551 oxepanyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000006684 polyhaloalkyl group Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 210000000063 presynaptic terminal Anatomy 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000025220 protein targeting to vacuole Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- NPWMTBZSRRLQNJ-UHFFFAOYSA-N pyroglutamine Chemical compound NC1CCC(=O)NC1=O NPWMTBZSRRLQNJ-UHFFFAOYSA-N 0.000 description 1
- VLJNHYLEOZPXFW-UHFFFAOYSA-N pyrrolidine-2-carboxamide Chemical compound NC(=O)C1CCCN1 VLJNHYLEOZPXFW-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 102200036624 rs104893875 Human genes 0.000 description 1
- 102200036626 rs104893877 Human genes 0.000 description 1
- 102200036620 rs104893878 Human genes 0.000 description 1
- 102200036623 rs201106962 Human genes 0.000 description 1
- 102220031971 rs431905511 Human genes 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 208000003755 striatonigral degeneration Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical compound C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000004685 tetrahydrates Chemical class 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 125000005305 thiadiazolinyl group Chemical group 0.000 description 1
- 125000005458 thianyl group Chemical group 0.000 description 1
- 125000001583 thiepanyl group Chemical group 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 125000005881 triazolinyl group Chemical group 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
Definitions
- Synucleinopathies are neurodegenerative diseases characterized by the abnormal accumulation of a-synuclein (a-Syn) aggregates in neurons and glial cells.
- ⁇ -Synuclein is a 140 amino acid protein preferentially expressed in neurons at pre-synaptic terminals where it is thought to play a role in regulating synaptic transmission (Bendor et al., Neuron 2013; 79:1044-66).
- a-Synuclein can form pathological aggregates in neurons known as Lewy bodies, which are characteristic of both Parkinson's Disease (PD) and dementia with Lewy bodies (DLB).
- the pathological aggregates consist of aggregated, insoluble accumulations of misfolded a-synuclein proteins in neurons, nerve fibers or glial cells and are a characteristic feature of synucleinopathies.
- Synucleinopathies include Parkinson’s disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA), the Lewy body variant of Alzheimer's disease (LBVAD), combined Parkinson's disease (PD) and Alzheimer's disease (AD), and neurodegeneration with brain iron accumulation type-1 (NBIA-1).
- PD and DLB a-Syn aggregates are in the neuronal cytoplasm and axonal processes into Lewy bodies and Lewy neurites, respectively, whereas a-Syn inclusions in oligodendroglia are the recognized neuropathologic hallmarks of MSA.
- the present disclosure stems from the recognition that a bispecific conjugate compound that includes an E3 ubiquitin ligase binding moiety that is based on an imide drug (e.g., lenalidomide, thalidomide, VHL ligand) and also includes a binder of a-synuclein may induce proteasome degradation of a-synuclein aggregates.
- an imide drug e.g., lenalidomide, thalidomide, VHL ligand
- the disclosure therefore provides compounds, compositions, and methods for the treatment of various neurodegenerative diseases associated with a-synuclein aggregates based on this discovery.
- the bispecific conjugate compounds described herein degrade the a-synuclein aggregates by removing a-synuclein aggregates or reducing the degree of a-synuclein aggregation to low levels in a cellular model and/or animal model, thereby possessing therapeutic potential in the treatment of patients with synucleinopathies including but not limited to Parkinson’s disease (PD), dementia with Lewy bodies (DLB), or multiple system atrophy (MSA).
- PD Parkinson’s disease
- DLB dementia with Lewy bodies
- MSA multiple system atrophy
- the present disclosure also provides methods to remove a-synuclein aggregation or reduce Lewy bodies or a-synuclein aggregate in a patient having Lewy body disease or risk of Lewy body disease, and methods to reduce dementia with Lewy bodies (DLB) or multiple system atrophy (MSA) or other synucleinopathies.
- DLB dementia with Lewy bodies
- MSA multiple system atrophy
- One aspect of the present disclosure is a compound of Formula A,
- EBM is an E3 ubiquitin ligase binding moiety
- L is a linker covalently attached to EBM and SBM; and SBM is an a-synuclein protein binding moiety of the formula: or a pharmaceutical acceptable salt, an enantiomer, a non-enantiomer, a tautomer, a racemate, a solvate, a metabolic precursor, a prodrug thereof, wherein covalently linked to L; and i .
- s a substituted or unsubstituted bicyclic fused aromatic ring containing at least 1 ring heteroatom selected from O, S, and N; is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; and is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; or is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; and is a substituted or unsubstituted bicyclic fused aromatic ring containing at least 1 ring heteroatom selected from O, S, and N.
- Another aspect of the disclosure is a compound of any one of the Formula (I)-(VI): or pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, or prodrugs thereof, wherein Li, L2, L3, X,
- composition comprising a compound of the disclosure, and a pharmaceutically acceptable excipient.
- Another aspect of the present disclosure is a method of treating, lessening the severity of, delaying the progression of, reducing the risk of developing, and/or delaying the onset of a disease characterized by the presence of Lewy bodies or pathological aggregates of a-synuclein, the method comprising administering to a subject in need thereof an effective amount of a compound or a composition of the present disclosure.
- Another aspect of the present disclosure is a method for synthesizing the compounds of the disclosure.
- Figure 1 shows the high content-based quantifications of aggregated a-synuclein species in combination with determination of nuclei count (% remaining cells) in differentiated ReNcell VM cells. Results showed that 24 hour treatment with test compounds 166362, 170357, 162640 and 180948, respectively, induced a concentration-dependent inhibition of MJFR14 immunoreactivity, indicative of decreased a-synuclein aggregation.
- Figures 2A-2D show the immunocytochemical images of cells treated with vehicle (0.1% DMSO) and test compounds 132168, 166362, and 170357, and immunostained with MJFR14, illustrating the reduction in a-synuclein expression following treatment with compounds 132168 and 166362.
- Figure 2A DMSO (0.1%)
- Figure 2B compound 132168 (3mM)
- Figure 2C compound 166362 (3mM)
- Figure 2D compound 170357 (10mM).
- Figure 3 shows the result of an in vivo a-synuclein degradation study. Upon treatment of compound 132168, insoluble a-synuclein fraction decreases 30% compared to DMSO vehicle control, indicating the reduction of insoluble a-synuclein aggregates.
- the present disclosure provides compounds, compositions, and methods useful for removing a-synuclein aggregates or reducing the degree of a-synuclein aggregation to low levels, thereby possessing therapeutic potential in the treatment of patients with synucleinopathies.
- bispecific conjugate compounds that can simultaneously bind a target protein (i.e., aggregated a-synuclein) and an E3 ubiquitin ligase.
- the bispecific conjugate compounds exhibit desirable functional properties including binding preferentially to a-synuclein aggregates, and allowing a-synuclein to be placed in proximity to the E3 ubiquitin ligase, thereby facilitating the selective ubiquitination and eventual proteasome-mediated degradation of a-synuclein aggregates.
- Methods described herein include the administration of a compound or a composition of the present disclosure to a subject to treat, alleviate or prevent a neurodegenerative disease or disorder characterized by the presence of Lewy bodies or pathological aggregates of a-synuclein.
- One aspect of the present disclosure is a compound of Formula A,
- EBM is an E3 ubiquitin ligase binding moiety
- L is a linker covalently attached to EBM and SBM
- SBM is an a-synuclein protein binding moiety of the formula: or a pharmaceutical acceptable salt, an enantiomer, a non-enantiomer, a tautomer, a racemate, a solvate, a metabolic precursor, a prodrug thereof, wherein is covalently linked to L;
- (i) is a substituted or unsubstituted bicyclic fused aromatic ring containing at least 1 ring heteroatom selected from O, S, and N; is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; and is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; or
- (ii) is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; and i .s a substi .tuted or unsubstituted bicyclic fused aromatic ring containing at least 1 ring heteroatom selected from O, S, and N.
- the substituted or unsubstituted bicyclic fused aromatic ring is a substituted or unsubstituted bicyclic 5-6 system.
- Non-limiting examples include
- SBM is of Formula B or Formula C wherein
- Z is C or N; U is O, S or CH; V is N or NH;
- J is CR 6 or N;
- X is CR 6 or N;
- Y is CR 6 or N; where at least one of J, X and Y is N, but J and Y are not N at the same time, X and Y are not N at the same time;
- R 6 is independently selected from the group consisting of H, NH2, Ci-6 alkyl and Ci-6 alkoxy, wherein NH2, Ci-6 alkyl or Ci-6 alkoxy is optionally substituted by 1 to 3 of C1-3 alkyl, C3-6 cycloalkyl and/or halo; and in Formula B, V is N, where Z and U are not heteroatoms at the same time; and in Formula C, V is N or NH; T is CH or N; where up to two of U, Z, V and T contain heteroatoms.
- EBM is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
- R 3 is H or Ci-6 alkyl; each occurrence of R 2 is independently selected from the group consisting of H,
- the compound is of any one of the Formula (I)-(VI):
- R is hydrogen, optionally substituted acyl, optionally substituted alkyl or a nitrogen protecting group
- L3 is a bond, - R-, -0-, or -S-, wherein R is hydrogen, optionally substituted acyl, optionally substituted alkyl or a nitrogen protecting group
- L2 is a substituted or unsubstituted Ci-50 hydrocarbon chain
- Z is C or N
- U is O, S or CH
- V is N, where Z and U are not heteroatoms at the same time
- K is CH or N
- Q is CH or N; where K and Q are not N at the same time
- each occurrence of R" is independently selected from the group consisting of H, OH, NH2, Ci-6 alkyl, Ci-6 alkylamino, Ci-6 alkoxy and halogen; k is 0, 1, 2 or 3;
- each occurrence of R' is independently selected from the group consisting of H, halogen, OH, Ci-6 alkyl,
- T is CH or N; where up to two of U, Z, V and T contain heteroatoms; K is CH or N; Q is CH or N; where K and Q are not N at the same time; each occurrence of R" is independently selected from the group consisting of H, OH, NH2, Ci-6 alkyl, Ci-6 alkylamino, Ci-6 alkoxy and halogen; k is 0, 1, 2 or 3; each occurrence of R 1 is independently selected from the group consisting of H, halogen, OH, Ci-6 alkyl, Ci-6 haloalkyl and Ci-6 alkoxy; m is 0, 1, 2, 3 or 4; each occurrence of R" is independently selected from the group consisting of H, halo, OH, NH2, Ci-6 alkyl, Ci-6 alkoxy, Ci-6 haloalkyl, Ci-6 alkylamino, C3-6 cycloalkyl, C3-6 cycloalkylamino and C3-6 heterocycloalkyl; n is 0, 1 or 2; J is
- R al is independently hydrogen, substituted or unsubstituted Ci-6 alkyl (e.g., substituted or unsubstituted methyl or ethy
- the compound is of the structure of Formula I.
- the compound is of the structure of Formula II.
- the compound is of the structure of Formula III.
- the compound is of the structure of Formula IV.
- the compound is of the structure of Formula V.
- the compound is of the structure of Formula VI.
- the moiety in Formula (I), (II) and (III) is [0030] In certain embodiments, the moiety in Formula (IV), (V) and (VI) is [0031] In certain embodiments, the moiety in Formulae (I)-(VI) is
- LI is a bond
- L3 is a bond
- L3 is - H-, -0-, or -S-.
- At least one chain atom of the hydrocarbon chain of L2 is independently replaced with -0-
- the chain of L2 comprises up to 50 consecutive covalently bonded atoms in length, excluding hydrogen atoms and substituents.
- L2 comprises up to, for example 46, 45, 40, 35, 32, 30, 25, 23, 20, 15, 14, 12, 11, 10, 9, 8, 7, 6, 5, 3 consecutive covalently bonded atoms in length, excluding hydrogen atoms and substituents.
- any of the atoms in L2 can be substituted. In certain embodiments, none of the atoms in the linker L2 are substituted. In certain embodiments, none of the carbon atoms in the linker are substituted.
- L2 is a linker that contains an asymmetric carbon/stereocenter, i.e., an sp3 hybridized carbon atom bearing 4 different groups attached thereto.
- the compound comprising such an L2 group is enantiomerically enriched or substantially enantiomerically enriched.
- the compound comprising such an L2 group is enantiomerically pure.
- the compound comprising such an L2 group is racemic.
- L2 comprises substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, substituted or unsubstituted heteroaryl ene, or substituted or unsubstituted heteroalkylene, or combinations thereof.
- L2 is substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, substituted or unsubstituted heteroaryl ene, or substituted or unsubstituted heteroalkylene.
- L2 is a linker selected from the group consisting of substituted and unsubstituted alkylene, substituted and unsubstituted alkenylene, substituted and unsubstituted alkynylene, substituted and unsubstituted heteroalkylene, substituted and unsubstituted heteroalkenylene, substituted and unsubstituted heteroalkynylene, substituted and unsubstituted heterocyclylene, substituted and unsubstituted carbocyclylene, substituted and unsubstituted arylene, substituted and unsubstituted heteroaryl ene, and combinations thereof.
- L2 being a combination of at least two instances of the divalent moieties described herein refers to a linker consisting of at least one instance of a first divalent moiety and at least one instance of a second divalent moiety, wherein the first and second divalent moieties are the same or different and are within the scope of the divalent moieties described herein, and the instances of the first and second divalent moieties are consecutive covalently attached to each other.
- L2 is a combination of alkylene and heteroalkylene linkers
- -heteroalkylene-alkylene-heteroalkylene- are all within the scope of L2, wherein each instance of alkylene in any one of the linkers may be the same or different, and each instance of heteroalkylene in any one of the linkers may be the same or different.
- L2 comprises at least one instance of substituted or unsubstituted alkylene, e.g., substituted or unsubstituted Ci-6 alkylene, substituted or unsubstituted C1-2 alkylene, substituted or unsubstituted C1-3 alkylene, substituted or unsubstituted C3-4 alkylene, substituted or unsubstituted C4-5 alkylene, substituted or unsubstituted C5-6alkylene, substituted or unsubstituted C3-6alkylene, or substituted or unsubstituted C4-6alkylene.
- substituted or unsubstituted alkylene e.g., substituted or unsubstituted Ci-6 alkylene, substituted or unsubstituted C1-2 alkylene, substituted or unsubstituted C1-3 alkylene, substituted or unsubstituted C3-4 alkylene, substituted or unsubstituted C4-5 alkylene, substituted or unsubstitute
- alkylene groups include unsubstituted alkylene groups such as methylene (-CH2-), ethylene (-(CH2)2-), n-propylene (-(CH2)3-), n-butylene (- (CH2)4-), n-pentylene (-(Cl [2)5-), and n-hexylene (-(CH2)6-).
- L2 comprises at least one instance of substituted or unsubstituted alkenylene, e g., substituted or unsubstituted C2-6 alkenyl ene, substituted or unsubstituted C1-3 alkenylene, substituted or unsubstituted C3-4 alkenylene, substituted or unsubstituted C4-5 alkenylene or substituted or unsubstituted C5-6 alkenylene.
- substituted or unsubstituted alkenylene e g., substituted or unsubstituted C2-6 alkenyl ene, substituted or unsubstituted C1-3 alkenylene, substituted or unsubstituted C3-4 alkenylene, substituted or unsubstituted C4-5 alkenylene or substituted or unsubstituted C5-6 alkenylene.
- L2 comprises at least one instance of substituted or unsubstituted alkynylene, e.g., substituted or unsubstituted C2-6 alkynylene, substituted or unsubstituted C2-3 alkynylene, substituted or unsubstituted C3-4 alkynylene, substituted or unsubstituted C4-5 alkynylene or substituted or unsubstituted C5-6 alkynylene.
- substituted or unsubstituted alkynylene e.g., substituted or unsubstituted C2-6 alkynylene, substituted or unsubstituted C2-3 alkynylene, substituted or unsubstituted C3-4 alkynylene, substituted or unsubstituted C4-5 alkynylene or substituted or unsubstituted C5-6 alkynylene.
- L2 comprises at least one instance of substituted or unsubstituted heteroalkylene, e.g., substituted or unsubstituted heteroCi- 6 alkylene, substituted or unsubstituted heteroCi-2alkylene, substituted or unsubstituted heteroC2- 3alkylene, substituted or unsubstituted heteroC3-4alkylene, substituted or unsubstituted heteroC4- salkylene or substituted or unsubstituted heteroCs ⁇ alkylene.
- substituted or unsubstituted heteroalkylene e.g., substituted or unsubstituted heteroCi- 6 alkylene, substituted or unsubstituted heteroCi-2alkylene, substituted or unsubstituted heteroC2- 3alkylene, substituted or unsubstituted heteroC3-4alkylene, substituted or unsubstituted heteroC4- salkylene or substituted or unsubstituted heteroCs ⁇ alkylene
- L2 comprises at least one instance of substituted or unsubstituted heteroalkenylene, e.g., substituted or unsubstituted heteroC2-6alkenylene, substituted or unsubstituted heteroCi-3alkenylene, substituted or unsubstituted heteroC3- 4alkenylene, substituted or unsubstituted heteroC4-salkenylene, or substituted or unsubstituted heteroC ealkenylene.
- substituted or unsubstituted heteroalkenylene e.g., substituted or unsubstituted heteroC2-6alkenylene, substituted or unsubstituted heteroCi-3alkenylene, substituted or unsubstituted heteroC3- 4alkenylene, substituted or unsubstituted heteroC4-salkenylene, or substituted or unsubstituted heteroC ealkenylene.
- L2 comprises at least one instance of substituted or unsubstituted heteroalkynylene, e.g., substituted or unsubstituted heteroC2-6alkynylene, substituted or unsubstituted heteroC2-3alkynylene, substituted or unsubstituted heteroCb-4 alkynylene, substituted or unsubstituted heteroCr-salkynylene, or substituted or unsubstituted heteroC5-6alkynylene.
- substituted or unsubstituted heteroalkynylene e.g., substituted or unsubstituted heteroC2-6alkynylene, substituted or unsubstituted heteroC2-3alkynylene, substituted or unsubstituted heteroCb-4 alkynylene, substituted or unsubstituted heteroCr-salkynylene, or substituted or unsubstituted heteroC5-6alkynylene.
- L2 comprises at least one instance of substituted or unsubstituted carbocyclylene, e.g., substituted or unsubstituted C3- 6 carbocyclylene, substituted or unsubstituted Cb-icarbocyclylene, substituted or unsubstituted C4- scarbocyclylene, or substituted or unsubstituted C5-6 carbocyclylene.
- substituted or unsubstituted carbocyclylene e.g., substituted or unsubstituted C3- 6 carbocyclylene, substituted or unsubstituted Cb-icarbocyclylene, substituted or unsubstituted C4- scarbocyclylene, or substituted or unsubstituted C5-6 carbocyclylene.
- L2 comprises at least one instance of substituted or unsubstituted heterocyclylene, e g., substituted or un substituted 3-6 membered heterocyclylene, substituted or unsubstituted 3-4 membered heterocyclylene, substituted or unsubstituted 4-5 membered heterocyclylene, or substituted or unsubstituted 5-6 membered heterocyclylene.
- at least one chain atom of the hydrocarbon chain of L2 is independently replaced with a 5-8 membered heterocyclyl group with 1-4 ring heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur.
- At least one chain atom of the hydrocarbon chain of L2 is independently replaced with a 6-membered heterocyclyl group with 1-3 ring heteroatoms selected from the group consisting of nitrogen and oxygen. In certain embodiments, at least one chain atom of the hydrocarbon chain of L2 is independently replaced with piperidine, piperazine or morpholine.
- L2 comprises at least one instance of substituted or unsubstituted arylene, e.g., substituted or unsubstituted phenylene.
- at least one chain atom of the hydrocarbon chain of L2 is independently replaced with an optionally substituted phenyl group.
- L2 comprises at least one instance of substituted or unsubstituted heteroaryl ene, e.g., substituted or unsubstituted 5- to 6-membered heteroaryl ene.
- L2 is an unsubstituted hydrocarbon chain, optionally wherein one or more chain atoms of the hydrocarbon chain are independently replaced with -NR al - and each instance ofR al is independently hydrogen, substituted or unsubstituted Ci-6 alkyl or a nitrogen protecting group, or optionally two instances of R al are taken together with their intervening atoms to form a substituted or unsubstituted heterocyclic or substituted or unsubstituted heteroaryl ring.
- at least one instance of R al is hydrogen.
- At least one instance of R al is substituted or unsubstituted Ci-6 alkyl (e.g., substituted or unsubstituted methyl or ethyl).
- at least one instance of R al is a nitrogen protecting group (e g., benzyl (Bn), t-butyl carbonate (BOC or Boc), benzyl carbamate (Cbz), 9-fluorenylmethyl carbonate (Fmoc), trifluoroacetyl, triphenylmethyl, acetyl or p-toluenesulfonamide (Ts)).
- L2 is an optionally substituted Ci-30 hydrocarbon chain, wherein one or more chain atoms of the hydrocarbon chain are independently replaced with -O- or -NR al - In certain embodiments, L2 is an unsubstituted Ci-30 hydrocarbon chain, wherein one or more chain atoms of the hydrocarbon chain are independently replaced with -O- or-NR al - In certain embodiments, L2 is an unsubstituted Ci-30 hydrocarbon chain, wherein at least one chain atom of the hydrocarbon chain is independently replaced with -0-.
- L2 is a substituted or unsubstituted C5-40 hydrocarbon chain.
- L2 is an unsubstituted Ci-26 hydrocarbon chain, wherein at least one chain atom of the hydrocarbon chain is independently replaced with - O — .
- the cyclic moiety herein refers to a cycloalkylene or a heterocycloalkylene, such as
- L2 is an all-carbon, substituted or unsubstituted Ci-45 hydrocarbon chain. In certain embodiments, L2 is an all-carbon, substituted or unsubstituted Ci-30 hydrocarbon chain. In certain embodiments, L2 is an all-carbon, substituted or unsubstituted Ci-26 hydrocarbon chain. In certain embodiments, L2 is an all-carbon, substituted or unsubstituted Ci-24 hydrocarbon chain. In certain embodiments, L2 is an all-carbon, substituted or unsubstituted Ci-20 hydrocarbon chain. In certain embodiments, L2 is an all-carbon, substituted or unsubstituted Ci-20 hydrocarbon chain.
- L2 is wherein g is 1, 2, 3, 4, 5, or 6. In certain embodiments, g is 1. In certain embodiments, g is 2. In certain embodiments, g is
- g is 4. In certain embodiments, g is 5. In certain embodiments, g is 6.
- L2 includes the moiety -NH-.
- L2 of the disclosure include, but are not limited to:
- L2 is of the formula:
- L2 is of the formula:
- L2 is of the formula: wherein g is 1, 2, 3, 4 or 5; h is 0, 1, 2, 3, 4 or 5; and f is 1, 2, 3, 4, 5, 6,
- L2 is of the formula:
- L2 is of the formula: wherein g is 1, 2, 3, 4, 5, 6, 7 or 8.
- L2 is of the formula:
- L2 is of the formula: herein g is 1, 2, 3, 4, 5, 6, 7 or 8; and f is 1, 2, 3, 4, 5, 6, 7 or 8.
- L2 is of the formula: , wherein g is 1, 2, 3, 4, 5, 6, 7 or 8.
- R is hydrogen, optionally substituted acyl, optionally substituted alkyl or a nitrogen protecting group
- L3 is a bond, -NR-, -0-, or -S-, wherein R is hydrogen, optionally substituted acyl, optionally substituted alkyl or a nitrogen protecting group
- L2 is a substituted or unsubstituted Ci-50 hydrocarbon chain
- Z is C orN
- U is O, S or CH; where Z and U are not heteroatoms at the same time
- Q is CH or N
- K is CH or N; where Q and K are not N at the same time
- each occurrence of R"' is independently selected from the group consisting of H, OH, NH2, Ci-6 alkyl, Ci-6 alkylamino, Ci-6 alkoxy and halogen; k is 0, 1, 2 or 3; each occurrence of R' is independently selected from the group consisting of H, halogen, OH, Ci-6 alkyl, Ci-6
- the compound of Formula 1-1 is of the following:
- R' is H, Ci-3 haloalkyl or C1-3 alkoxy, preferably H, CF3, CCb, methoxy or ethoxy, more preferably H, CF3 or methoxy.
- An embodiment of the disclosure is the compound of Formula 1, wherein m is 0, 1, 2, 3 or 4, preferably 0 or 1.
- An embodiment of the disclosure is the compound of Formula 1, wherein R" is H, halo, OH, NH2, Ci-3 alkoxy, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino and C3-5 heterocycloalkyl, preferably H, F, Cl, NH2, methoxy, ethoxy, methylamino, dimethylamino, ethylamino, diethylamino, cyclopropyl, cyclobutyl or cyclopentyl, more preferably H, F, dimethylamino or cyclopropyl.
- An embodiment of the disclosure is the compound of Formula 1, wherein n is 0, 1 or 2, preferably 0 or 1.
- An embodiment of the disclosure is the compound of Formula 1, wherein R'" is H, OH or halogen, preferably H, OH, F or Cl, more preferably H.
- An embodiment of the disclosure is the compound of Formula 1, wherein k is 0, 1, 2 or 3, preferably 0 or 1.
- An embodiment of the disclosure is the compound of Formula 1, wherein R 1 is O,
- An embodiment of the disclosure is the compound of Formula 1, wherein A is O,
- An embodiment of the disclosure is the compound of Formula 1, wherein m2 is 2, 3, 4 or 6, preferably 2 or 6.
- An embodiment of the disclosure is the compound of Formula 1, wherein R 3 is H or Ci-3 alkyl, preferably H or methyl, more preferably H.
- An embodiment of the disclosure is the compound of Formula 1 having the structure as shown in Formula 1-1, U is O, S or CH; Z is C or N; where U and Z are not heteroatoms at the same time; R 1 is H, Ci-3 haloalkyl or C1-3 alkoxy; R" is H, F, Cl, OH, NH2, C1-3 alkoxy, methylamino, dimethylamino, diethylamino or cyclopropylamino; n is 0, 1 or 2.
- An embodiment of the disclosure is the compound of Formula 1-1, wherein m2 is 2, 3, 4 or 6, preferably 2 or 6.
- An embodiment of the disclosure is the compound of Formula 1-1, wherein R 3 is H or methyl.
- An embodiment of the disclosure is the compound of Formula 1-1, wherein A is O or
- An embodiment of the disclosure is the compound of Formula 1-1, wherein R 1 is
- An embodiment of the disclosure is the compound of Formula 1-1, wherein R 1 is O, NH,
- An embodiment of the disclosure is the compound of Formula 1-1, wherein Z is N,
- U is CH [0097]
- An embodiment of the disclosure is the compound of Formula 1-1, wherein Z is C, U is S or O.
- An embodiment of the disclosure is the compound of Formula 1-1, wherein R" is H, F, Cl, OF1, NH2, methoxy, methylamino, dimethylamino, diethylamino, cyclopropyl or cyclopropylamino, preferably H, F, methylamino, dimethylamino or cyclopropylamino.
- R' is H, F, Cl, OF1, NH2, methoxy, methylamino, dimethylamino, diethylamino, cyclopropyl or cyclopropylamino, preferably H, F, methylamino, dimethylamino or cyclopropylamino.
- R' is H, methoxy or CF3.
- An embodiment of the disclosure is the compound of Formula 5, wherein R 3 is H or Ci-3 alkyl, preferably H or methyl.
- An embodiment of the disclosure is the compound of Formula 5, wherein A is O, H
- An embodiment of the disclosure is the compound of
- An embodiment of the disclosure is the compound of Formula 5, wherein m4 is 0,
- An embodiment of the disclosure is the compound of Formula 5, wherein m5 is 0,
- An embodiment of the disclosure is the compound of Formula 5, wherein m3 is 1,
- An embodiment of the disclosure is the compound of Formula 5, wherein R 1 is O,
- An embodiment of the disclosure is the compound of Formula 5, wherein R 1 " is H, OH, Ci-3 alkyl, C1-3 alkoxy or halogen, preferably H, methyl, methoxy or F, more preferably H.
- An embodiment of the disclosure is the compound of Formula 5, wherein k is 0, 1, 2 or 3, preferably 0 or 1.
- An embodiment of the disclosure is the compound of Formula 5, wherein Z is C, U is O or S.
- An embodiment of the disclosure is the compound of Formula 5, wherein Z is N,
- An embodiment of the disclosure is the compound of Formula 5, wherein R' is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy, preferably H, F, CF3, CCh, methyl or methoxy, more preferably H or CF3.
- An embodiment of the disclosure is the compound of Formula 5, wherein m is 0, 1, 2 or 3, preferably 0 or 1.
- An embodiment of the disclosure is the compound of Formula 5, wherein R" is H, halo, OH, NH2, Ci-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl, preferably H, F, OH, NH2, methyl, methoxy, CF3, CCb, methylamino, cyclopropyl or dimethylamino, more preferably H, F, CF3, cyclopropyl, cyclopropylamino or dimethylamino.
- An embodiment of the disclosure is the compound of Formula 5, wherein n is 0, 1 or 2, preferably 0 or 1.
- An embodiment of the disclosure is the compound of Formula 5 having the structure as shown in Formula 5-1, are not heteroatoms at the same time;
- R'" is H, OH, C1-3 alkyl, C1-3 alkoxy or halogen;
- R' is H, halogen, OH, C1-3 alkyl, Ci-3haloalkyl or C1-3 alkoxy;
- R" is H, halo, OH, NH2, C1-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino and C3-5 heterocycloalkyl;
- n is 0, 1 or 2.
- An embodiment of the disclosure is the compound of Formula 5-1, wherein A is O.
- An embodiment of the disclosure is the compound of Formula 5-1, wherein m5 is 0 or 1.
- An embodiment of the disclosure is the compound of Formula 5-1, wherein m4 is 0 or 3.
- An embodiment of the disclosure is the compound of Formula 5-1, wherein m3 is 3, 5.
- An embodiment of the disclosure is the compound of Formula 5-1, wherein R 1 is
- An embodiment of the disclosure is the compound of Formula 5-1, wherein Z is C, U is O or S.
- An embodiment of the disclosure is the compound of Formula 5-1, wherein Z is N, U is CH.
- An embodiment of the disclosure is the compound of Formula 5-1, wherein R' is H, halogen, C1-3 alkyl, C1-3 fluoroalkyl or C1-3 alkoxy, preferably H, methyl, CF3, methyl or methoxy, more preferably H or CF3.
- An embodiment of the disclosure is the compound of Formula 5-1, wherein R" is H, halo, OH, NH2, C1-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl, preferably H, F, CF3, amino, methylamino, dimethylamino, cyclopropyl or cyclopropylamino, more preferably H, F, CF3, dimethylamino, cyclopropylamino or cyclopropyl.
- R 3 is H or Ci-3 alkyl, preferably H or methyl.
- An embodiment of the disclosure is the compound of Formula 6, wherein A is O, preferably O or NH.
- An embodiment of the disclosure is the compound of Formula 6, wherein m2 is 1, 2, 3, 4, 5, 6 or 7, preferably 2 or 6.
- An embodiment of the disclosure is the compound of Formula 6, wherein R 1 is O, , preferably O or NH.
- An embodiment of the disclosure is the compound of Formula 6, wherein Z is C or N, and U is O, S or CH, where Z and U are not heteroatoms at the same time; preferably Z is C and U is S.
- An embodiment of the disclosure is the compound of Formula 6, wherein R'" is H, OH, Ci-3 alkyl, C1-3 alkoxy or halogen, preferably H, methyl, methoxy or F, more preferably H.
- An embodiment of the disclosure is the compound of Formula 6, wherein R is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy, preferably H, F, CF3, CCb, methyl or methoxy, more preferably H or CF3.
- An embodiment of the disclosure is the compound of Formula 6, wherein m is 0, 1, 2 or 3, preferably 0 or 1.
- An embodiment of the disclosure is the compound of Formula 6, wherein R" is H, halo, OH, NH2, Ci-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl, preferably H, F, OH, NH2, methyl, methoxy, CF3, CCb, methylamino, cyclopropyl, cyclopropylamino or dimethylamino, more preferably H,
- An embodiment of the disclosure is the compound of Formula 6, wherein n is 0 or
- An embodiment of the disclosure is the compound of Formula 6 having the structure as shown in Formula 6-1, R" is H, OH, Ci-3 alkyl, C1-3 alkoxy or halogen; k is 0, 1, 2 or 3; Z is C or N; U is O, S or CH; where Z and U are not heteroatoms at the same time; R 1 is H, halogen, OH, C1-3 alkyl, Ci-3haloalkyl or C1-3 alkoxy; m is 0, 1, 2 or 3; R" is H, halo, OH, NH2, C1-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl; n is 0, 1 or 2.
- R 3 is H or C1-3 alkyl; Yi is CH2 or ; R" is H, OH, C1-3 alkyl, C1-3 alkoxy or halogen; k is 0, 1, 2 or 3; Z is C or N; U is O, S or CH; where Z and U are not heteroatoms at the same time; R 1 is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy; m is 0, 1, 2 or 3; R" is H, halo, OH, NH2, C1-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl; n is 0, 1 or 2. [0138] An embodiment of the disclosure is the compound of Formula 6-1, wherein R 3 is H or methyl.
- An embodiment of the disclosure is the compound of Formula 6-1, wherein A is O or NI I.
- An embodiment of the disclosure is the compound of Formula 6-1, wherein m2 is 2 or 6.
- An embodiment of the disclosure is the compound of Formula 6-1, wherein R 1 is O, or NH.
- An embodiment of the disclosure is the compound of Formula 6-1, wherein R is
- An embodiment of the disclosure is the compound of Formula 6-1, wherein m is 0, 1, 2 or 3, preferably 0 or 1.
- An embodiment of the disclosure is the compound of Formula 6-1, wherein R" is H, halo, OH, NH2, C1-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl, preferably H, F, CF3, methoxy, methyl, dimethylamino, cyclopropyl, cyclopropylamino or methylamino, more preferably H, CF3, F, dimethylamino, cyclopropyl or cyclopropylamino, most preferably H, dimethylamino, cyclopropyl or cyclopropylamino.
- An embodiment of the disclosure is the compound of Formula 6-1, wherein n is 0 or 1.
- An embodiment of the disclosure is the compound of Formula 6-1, wherein R" substitutes at the adjacent position to the N atom.
- An embodiment of the disclosure is the compound of Formula 8, wherein R 3 is H or Ci-3 alkyl, preferably H or methyl.
- An embodiment of the disclosure is the compound of Formula 8, wherein Yi is preferably CH2. [0149] An embodiment of the disclosure is the compound of Formula 8, wherein A is O,
- An embodiment of the disclosure is the compound of Formula 8, wherein m2 is 1, 2, 3 or 4, preferably 2.
- An embodiment of the disclosure is the compound of Formula 8, wherein R 1 is O, H, preferably O.
- An embodiment of the disclosure is the compound of Formula 8, wherein R'" is H, OH, Ci-3 alkyl, C1-3 alkoxy or halogen, preferably H, methyl, methoxy or F, more preferably
- An embodiment of the disclosure is the compound of Formula 8, wherein k is 0 or
- An embodiment of the disclosure is the compound of Formula 8, wherein Z is C or N; U is O, S or CH; where Z and U are not heteroatoms at the same time; preferably Z is N and U is CH; preferably Z is C and U is S.
- An embodiment of the disclosure is the compound of Formula 8, wherein R' is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy, preferably H, F, CF3, CCb, methyl or methoxy, more preferably H or CF3.
- An embodiment of the disclosure is the compound of Formula 8, wherein m is 0, 1 or 2.
- An embodiment of the disclosure is the compound of Formula 8, wherein R" is H, halo, OH, NH2, Ci-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl, preferably H, F, OH, NH2, methyl, methoxy, CF3, CCb, methylamino, dimethylamino, cyclopropyl or cyclopropylamino, more preferably H,
- An embodiment of the disclosure is the compound of Formula 8, wherein n is 0, 1 or 2.
- An embodiment of the disclosure is the compound of Formula 10, wherein R 3 is H or Ci-3 alkyl, preferably H or methyl.
- An embodiment of the disclosure is the compound of Formula 10, wherein Yi is , preferably CH2.
- An embodiment of the disclosure is the compound of Formula 10, wherein each A is independently ,
- An embodiment of the disclosure is the compound of Formula 10, wherein A is preferably
- An embodiment of the disclosure is the compound of Formula 10, wherein m5 is 0 or 1.
- An embodiment of the disclosure is the compound of Formula 10, wherein m4 is 0 or 1.
- An embodiment of the disclosure is the compound of Formula 10, wherein m3 is 1, 2, 3, 4 or 5, preferably 4.
- An embodiment of the disclosure is the compound of Formula 10, wherein R 1 is
- An embodiment of the disclosure is the compound of Formula 10, wherein R" is H, OH, C1-3 alkyl, C1-3 alkoxy or halogen, preferably H, methyl, methoxy or F, more preferably H.
- An embodiment of the disclosure is the compound of Formula 10, wherein k is 0 or 1.
- An embodiment of the disclosure is the compound of Formula 10, wherein Z is C,
- U is S or O.
- An embodiment of the disclosure is the compound of Formula 10, wherein Z is N,
- An embodiment of the disclosure is the compound of Formula 10, wherein R' is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy, preferably H, F, CF3, CCb, methyl or methoxy, more preferably H or CF3.
- An embodiment of the disclosure is the compound of Formula 10, wherein m is 0 or 1.
- An embodiment of the disclosure is the compound of Formula 10, wherein R" is H, halo, OH, NH2, Ci-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl, preferably H, F, OH, NH2, methyl, methoxy, CF3, CCb, methylamino, cyclopropyl, cyclopropylamino or dimethylamino, more preferably H,
- An embodiment of the disclosure is the compound of Formula 10, wherein n is 0 or 1.
- An embodiment of the disclosure is the compound of Formula 13, wherein R 3 is H or Ci-3 alkyl, preferably H or methyl.
- An embodiment of the disclosure is the compound of Formula 13, wherein Yi is preferably CH2.
- An embodiment of the disclosure is the compound of Formula 13, wherein A is O,
- An embodiment of the disclosure is the compound of Formula 13, wherein m2 is 1, 2, 3 or 4, preferably 1.
- An embodiment of the disclosure is the compound of Formula 13, wherein R 1 is
- An embodiment of the disclosure is the compound of Formula 13, wherein R"' is
- H OH, Ci-3 alkyl, C1-3 alkoxy or halogen, preferably H, methyl, methoxy or F, more preferably H.
- An embodiment of the disclosure is the compound of Formula 13, wherein k is 0,
- An embodiment of the disclosure is the compound of Formula 13, wherein Z is C, U is S or O.
- An embodiment of the disclosure is the compound of Formula 13, wherein Z is N, U is CH
- An embodiment of the disclosure is the compound of Formula 13, wherein R' is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy, preferably H, F, CF3, CCb, methyl or methoxy, more preferably H or CF3.
- An embodiment of the disclosure is the compound of Formula 13, wherein m is 0, 1, 2 or 3, preferably 0 or 1.
- An embodiment of the disclosure is the compound of Formula 13, wherein R" is H, halo, OH, NH2, Ci-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl, preferably H, F, OH, NH2, methyl, methoxy, CF3, CCb, methylamino, cyclopropyl, cyclopropylamino or dimethylamino, more preferably H,
- An embodiment of the disclosure is the compound of Formula 13, wherein n is 0,
- An embodiment of the compound of Formula II-l is of the following Formula 3, wherein R 1 is O, NH,
- An embodiment of the disclosure is the compound of Formula 3, wherein R 2 is H, OH, Ci-3 alkyl, C1-3 alkoxy, C1-3 alkylamino or NH2, preferably H, OH orML ⁇ .
- An embodiment of the disclosure is the compound of Formula 3, wherein m6 is 0,
- An embodiment of the disclosure is the compound of Formula 3, wherein R 1 is O or NH.
- An embodiment of the disclosure is the compound of Formula 3, wherein R' is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy, preferably H, halogen or C1-3 fluoroalkyl, more preferably H or F.
- An embodiment of the disclosure is the compound of Formula 3, wherein m is 0, 1,
- An embodiment of the disclosure is the compound of Formula 3, wherein R" is H, halo, OH, NH2, Ci-3 alkoxy, C3-5 cycloalkyl, C3-5 cycloalkylamino or C1-3 alkylamino, preferably H, halo, methylamino, dimethylamino, cyclopropylamino or cyclopropyl, more preferably H, F or dimethylamino.
- An embodiment of the disclosure is the compound of Formula 3, wherein n is 0, 1, 2 or 3, preferably 0, 1 or 2.
- An embodiment of the disclosure is the compound of Formula 3, wherein Z is C,
- U is O or S.
- An embodiment of the disclosure is the compound of Formula 3, wherein Z is N,
- An embodiment of the disclosure is the compound of Formula 3, wherein R'" is H, OH, Ci-3 alkyl, C1-3 alkoxy or halogen, preferably H, F, methyl or methoxy, more preferably H.
- An embodiment of the disclosure is the compound of Formula 3 having the structure as shown in Formula 3-1, wherein R 2 is H, OH, C1-3 alkyl, C1-3 alkoxy, C1-3 alkylamino or H2; m6 is 0, 1, 2 or 3; Yi
- R" is H, halo, OH, NH2, C1-3 alkoxy, C1-3 haloalkyl, C3-5 cycloalkyl, C3-5 cycloalkylamino or C1-3 alkylamino; n is 0, 1 or 2.
- An embodiment of the disclosure is the compound of Formula 3-1, wherein R 2 is H, NH2 or OH.
- An embodiment of the disclosure is the compound of Formula 3-1, wherein m6 is 0 or 1.
- An embodiment of the disclosure is the compound of Formula 3-1, wherein when substituted at the following position in the phenyl:
- An embodiment of the disclosure is the compound of Formula 3-1, wherein R 1 is O or NH.
- An embodiment of the disclosure is the compound of Formula 3-1, wherein R" is F, dimethylamino, methylamino, cyclopropyl or cyclopropylamino.
- An embodiment of the disclosure is the compound of Formula 3-1, wherein n is 0, 1, or 2.
- An embodiment of the disclosure is the compound of Formula 15, wherein R 1 is , preferably O or NH.
- An embodiment of the disclosure is the compound of Formula 15, wherein R" is H, OH, Ci-3 alkyl, C1-3 alkoxy or halogen, preferably H, F, methyl or methoxy, more preferably H.
- An embodiment of the disclosure is the compound of Formula 15, wherein Z is C, U is O or S.
- An embodiment of the disclosure is the compound of Formula 15, wherein Z is N,
- An embodiment of the disclosure is the compound of Formula 15, wherein R' is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy, preferably H, halogen or C1-3 fluoroalkyl, more preferably H, CF3 or F.
- An embodiment of the disclosure is the compound of Formula 15, wherein m is 0, 1, 2 or 3, preferably 0, 1 or 2, more preferably 0 or 1.
- An embodiment of the disclosure is the compound of Formula 15, wherein R" is H, halo, OH, NH2, Ci-3 alkoxy, C3-5 cycloalkyl, C3-5 cycloalkylamino or C1-3 alkylamino, preferably H, halo, methylamino, dimethylamino, cyclopropylamino or cyclopropyl, more preferably H, F, methylamino, cyclopropylamino or dimethylamino, most preferably H or dimethylamino.
- An embodiment of the disclosure is the compound of Formula 15, wherein n is 0,
- An embodiment of the compound of Formula IV-1 is of the following Formula 2, 7, 9, 11, 12 or 14,
- An embodiment of the disclosure is the compound of Formula 2, wherein R 3 is H or Ci-3 alkyl, preferably H or methyl.
- An embodiment of the disclosure is the compound of Formula 2, wherein Yi is [0219]
- An embodiment of the disclosure is the compound of Formula 2, wherein m2 is 2, 3, 4, 5 or 6, preferably 2 or 6.
- An embodiment of the disclosure is the compound of Formula 2, wherein R 1 is O, preferably NH.
- An embodiment of the disclosure is the compound of Formula 2, wherein R" is H, halo, OH, NH2, Ci-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl, preferably H, F, OH, H2, methyl, methoxy, CF3, CCb, methylamino, dimethylamino, cyclopropyl or cyclopropylamino, more preferably H,
- An embodiment of the disclosure is the compound of Formula 2, wherein n is 0, 1 or 2, preferably 0 or 1.
- An embodiment of the disclosure is the compound of Formula 2, wherein R' is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy, preferably H, F, CF3, CCb, methyl or methoxy, more preferably H or CF3.
- An embodiment of the disclosure is the compound of Formula 2, wherein m is 0, 1, 2 or 3, preferably 0, 1 or 2.
- An embodiment of the disclosure is the compound of Formula 2, wherein Z is C,
- U is O or S
- W is CH
- An embodiment of the disclosure is the compound of Formula 2, wherein Z is N,
- An embodiment of the disclosure is the compound of Formula 2, wherein Z is C, W is N, U is CH.
- An embodiment of the disclosure is the compound of Formula 2, wherein R'" is H, OH, NH2, Ci-3 alkyl, C1-3 alkylamino, C1-3 alkoxy or halogen, preferably H, F, methoxy, methylamino or dimethylamino.
- An embodiment of the disclosure is the compound of Formula 2, wherein k is 0, 1, 2 or 3, preferably 0, 1 or 2, more preferably 0 or 1.
- An embodiment of the disclosure is the compound of Formula 7, wherein R 3 is H or Ci-3 alkyl, preferably H or methyl.
- An embodiment of the disclosure is the compound of Formula 7, wherein Yi is
- An embodiment of the disclosure is the compound of Formula 7, wherein A is O,
- An embodiment of the disclosure is the compound of Formula 7, wherein m2 is 2, 3, 4, 5 or 6, preferably 2 or 3.
- An embodiment of the disclosure is the compound of Formula 7, wherein R 1 is O,
- NH preferably NH.
- An embodiment of the disclosure is the compound of Formula 7, wherein R" is H, halo, OH, NH2, Ci-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl, preferably H, F, OH, NH2, methyl, methoxy, CF3, CCb, methylamino, dimethylamino, cyclopropyl or cyclopropylamino, more preferably H,
- An embodiment of the disclosure is the compound of Formula 7, wherein n is 0, 1, or 2, preferably 0 or 1.
- An embodiment of the disclosure is the compound of Formula 7, wherein R' is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy, preferably H, F, CF3, CCb, methyl or methoxy, more preferably H or CF3.
- An embodiment of the disclosure is the compound of Formula 7, wherein m is 0, 1, 2 or 3, preferably 0, 1 or 2.
- An embodiment of the disclosure is the compound of Formula 7, wherein Z is C,
- U is O or S, W is CH.
- An embodiment of the disclosure is the compound of Formula 7, wherein Z is N, U is CH, W is CH.
- An embodiment of the disclosure is the compound of Formula 7, wherein Z is C, W is N, U is CH.
- An embodiment of the disclosure is the compound of Formula 7, wherein R'" is H, OH, NH2, Ci-3 alkyl, C1-3 alkylamino, C1-3 alkoxy or halogen, preferably H, F, methoxy, methylamino or dimethylamino.
- An embodiment of the disclosure is the compound of Formula 7, wherein k is 0, 1, 2 or 3, preferably 0, 1 or 2, more preferably 0 or 1.
- An embodiment of the disclosure is the compound of Formula 9, wherein R 3 is H or Ci-3 alkyl, preferably H or methyl.
- An embodiment of the disclosure is the compound of Formula 9, wherein Yi is
- An embodiment of the disclosure is the compound of Formula 9, wherein A is O,
- An embodiment of the disclosure is the compound of Formula 9, wherein m2 is 2, 3, 4, 5 or 6, preferably 2 or 3.
- An embodiment of the disclosure is the compound of Formula 9, wherein R 1 is O, , preferably NH.
- An embodiment of the disclosure is the compound of Formula 9, wherein R" is H, halo, OH, NH2, Ci-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl, preferably H, F, OH, NH2, methyl, methoxy, CF3, CCb, methylamino, dimethylamino, cyclopropyl or cyclopropylamino, more preferably H, F, CF3, cyclopropyl or cyclopropylamino.
- An embodiment of the disclosure is the compound of Formula 9, wherein n is 0, 1, or 2, preferably 0 or 1.
- An embodiment of the disclosure is the compound of Formula 9, wherein R' is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy, preferably H, F, CF3, CCb, methyl or methoxy, more preferably H or CF3.
- An embodiment of the disclosure is the compound of Formula 9, wherein m is 0, 1, 2 or 3, preferably 0, 1 or 2.
- An embodiment of the disclosure is the compound of Formula 9, wherein Z is C,
- U is O or S
- W is CH
- An embodiment of the disclosure is the compound of Formula 9, wherein Z is N,
- An embodiment of the disclosure is the compound of Formula 9, wherein Z is C, W is N, U is CH.
- An embodiment of the disclosure is the compound of Formula 9, wherein R'" is H, OH, NH2, Ci-3 alkyl, C1-3 alkylamino, C1-3 alkoxy or halogen, preferably H, F, methoxy, methylamino or dimethylamino.
- An embodiment of the disclosure is the compound of Formula 9, wherein k is 0, 1, 2 or 3, preferably 0, 1 or 2, more preferably 0 or 1.
- An embodiment of the disclosure is the compound of Formula 11, wherein R 3 is H or Ci-3 alkyl, preferably H or methyl.
- An embodiment of the disclosure is the compound of Formula 11, wherein Yi is
- An embodiment of the disclosure is the compound of Formula 11, wherein A is O,
- An embodiment of the disclosure is the compound of Formula 11, wherein m2 is 2, 3, 4, 5 or 6, preferably 2 or 3.
- An embodiment of the disclosure is the compound of Formula 11, wherein R 1 is
- An embodiment of the disclosure is the compound of Formula 11, wherein R" is H, halo, OH, NH2, Ci-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl, preferably H, F, OH, NH2, methyl, methoxy, CF3, CCb, methylamino, dimethylamino, cyclopropyl or cyclopropylamino, more preferably H,
- An embodiment of the disclosure is the compound of Formula 11, wherein n is 0,
- An embodiment of the disclosure is the compound of Formula 11, wherein R' is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy, preferably H, F, CF3, CCb, methyl or methoxy, more preferably H or CF3.
- An embodiment of the disclosure is the compound of Formula 11, wherein m is 0, 1, 2 or 3, preferably 0, 1 or 2.
- An embodiment of the disclosure is the compound of Formula 11, wherein Z is C, U is O or S, W is CH.
- An embodiment of the disclosure is the compound of Formula 11, wherein Z is N, U is CH, W is CH
- An embodiment of the disclosure is the compound of Formula 11, wherein Z is C, W is N, U is CH.
- An embodiment of the disclosure is the compound of Formula 11, wherein R" is
- An embodiment of the disclosure is the compound of Formula 11, wherein k is 0,
- An embodiment of the disclosure is the compound of Formula 12, wherein R 3 is H or Ci-3 alkyl, preferably H or methyl. [0273] An embodiment of the disclosure is the compound of Formula 12, wherein Yi is , preferably CH2.
- An embodiment of the disclosure is the compound of Formula 12, wherein each A is independently O, NH, An embodiment of the disclosure is the compound of Formula 12, wherein A is O, NH, , preferably O.
- An embodiment of the disclosure is the compound of Formula 12, wherein m3 is 1, 2, 3, 4, 5 or 6, preferably 2 or 3.
- An embodiment of the disclosure is the compound of Formula 12, wherein m4 is 0 or 1, 2 or 3, preferably 0 or 3.
- An embodiment of the disclosure is the compound of Formula 12, wherein m5 is 0 or 1, 2 or 3, preferably 0 or 1.
- An embodiment of the disclosure is the compound of Formula 12, wherein R 1 is
- An embodiment of the disclosure is the compound of Formula 12, wherein R" is H, halo, OH, NH2, Ci-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl, preferably H, F, OH, NH2, methyl, methoxy, CF3, CCb, methylamino, dimethylamino, cyclopropyl or cyclopropylamino, more preferably H,
- An embodiment of the disclosure is the compound of Formula 12, wherein n is 0,
- An embodiment of the disclosure is the compound of Formula 12, wherein R' is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy, preferably H, F, CF3, CCb, methyl or methoxy, more preferably H or CF3.
- R' is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy, preferably H, F, CF3, CCb, methyl or methoxy, more preferably H or CF3.
- An embodiment of the disclosure is the compound of Formula 12, wherein m is 0, 1, 2 or 3, preferably 0, 1 or 2.
- An embodiment of the disclosure is the compound of Formula 12, wherein Z is C, U is O or S, W is CH.
- An embodiment of the disclosure is the compound of Formula 12, wherein Z is N, U is CH, W is CH
- An embodiment of the disclosure is the compound of Formula 12, wherein Z is C, W is N, U is CH.
- An embodiment of the disclosure is the compound of Formula 12, wherein R"' is
- An embodiment of the disclosure is the compound of Formula 12, wherein k is 0,
- An embodiment of the disclosure is the compound of Formula 14, wherein R 3 is H or C1-3 alkyl, preferably H or methyl.
- An embodiment of the disclosure is the compound of Formula 14, wherein Yi is , preferably CH2.
- An embodiment of the disclosure is the compound of Formula 14, wherein each A is independently O, NH, An embodiment of the disclosure is the compound of Formula 14, wherein A is O, NH , preferably O.
- An embodiment of the disclosure is the compound of Formula 14, wherein m3 is 1, 2, 3, 4, 5 or 6, preferably 2, 3 or 4.
- An embodiment of the disclosure is the compound of Formula 14, wherein m4 is 0 , 1, 2, 3 or 4, preferably 0 or 3.
- An embodiment of the disclosure is the compound of Formula 14, wherein m5 is 0 or 1, 2 or 3, preferably 0 or 1.
- An embodiment of the disclosure is the compound of Formula 14, wherein R 1 is
- An embodiment of the disclosure is the compound of Formula 14, wherein R" is H, halo, OH, NH2, Ci-3 alkyl, C1-3 alkoxy, C1.3 haloalkyl, C1.3 alkylamino, C3-5 cycloalkyl, C3-5 cycloalkylamino or C3-5 heterocycloalkyl, preferably H, F, OH, H2, methyl, methoxy, CF3, CCb, methylamino, dimethylamino, cyclopropyl or cyclopropylamino, more preferably H,
- An embodiment of the disclosure is the compound of Formula 14, wherein n is 0,
- An embodiment of the disclosure is the compound of Formula 14, wherein R' is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy, preferably H, F, CF3, CCb, methyl or methoxy, more preferably H or CF3.
- An embodiment of the disclosure is the compound of Formula 14, wherein m is 0, 1, 2 or 3, preferably 0, 1 or 2.
- An embodiment of the disclosure is the compound of Formula 14, wherein Z is C, U is O or S, W is CH.
- An embodiment of the disclosure is the compound of Formula 14, wherein Z is N, U is CH, W is CH
- An embodiment of the disclosure is the compound of Formula 14, wherein Z is C, W is N, U is CH.
- An embodiment of the disclosure is the compound of Formula 14, wherein R" is
- An embodiment of the disclosure is the compound of Formula 14, wherein k is 0,
- An embodiment of the disclosure is the compound of Formula 4, wherein R 2 is H, OH, Ci-3 alkyl, C1-3 alkoxy, C1-3 alkylamino or NH2, preferably H, OH orML ⁇ .
- An embodiment of the disclosure is the compound of Formula 4, wherein m6 is 0,
- An embodiment of the disclosure is the compound of Formula 4, wherein R 1 is O,
- NH preferably O or NH.
- An embodiment of the disclosure is the compound of Formula 4, wherein R' is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy, preferably H, halogen or C1-3 fluoroalkyl, more preferably H or F.
- An embodiment of the disclosure is the compound of Formula 4, wherein m is 0, 1,
- An embodiment of the disclosure is the compound of Formula 4, wherein R" is H, halo, OH, NH2, Ci-3 alkoxy, C3-5 cycloalkyl, C3-5 cycloalkylamino or C1-3 alkylamino, preferably H, halo, methylamino, dimethylamino, cyclopropylamino or cyclopropyl, more preferably H, F or dimethylamino.
- An embodiment of the disclosure is the compound of Formula 4, wherein n is 0, 1, or 2, preferably 0 or 1.
- An embodiment of the disclosure is the compound of Formula 4, wherein Z is C,
- U is O or S, W is CH [0313]
- An embodiment of the disclosure is the compound of Formula 4, wherein Z is N, U is CH, W is CH
- An embodiment of the disclosure is the compound of Formula 4, wherein Z is C, U is CH, W is N.
- An embodiment of the disclosure is the compound of Formula 4, wherein R'" is H, OH, NH2, Ci-3 alkyl, C1-3 alkylamino, C1-3 alkoxy or halogen, preferably H, F, methoxy, methylamino or dimethylamino.
- An embodiment of the disclosure is the compound of Formula 4, wherein k is 0, 1, 2 or 3, preferably 0, 1 or 2, more preferably 0 or 1.
- An embodiment of the disclosure is the compound of Formula 4 having the structure as shown in Formula 4-1, alkoxy, C1-3 haloalkyl, C1-3 alkylamino or C3-5 heterocycloalkyl; n is 0, 1 or 2; R is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy; m is n is 0, 1 or 2; U is O or S; R 1 " is H, OH, NH2, Ci-3 alkyl, C1-3 alkylamino, C1-3 alkoxy or halogen; k is 0, 1, 2, 3 or 4.
- An embodiment of the disclosure is the compound of Formula 4-1, wherein R 1 is NH.
- An embodiment of the disclosure is the compound of Formula 4-1, wherein R" is H.
- An embodiment of the disclosure is the compound of Formula 4-1, wherein R' is H.
- An embodiment of the disclosure is the compound of Formula 4-1, wherein R 2 is
- An embodiment of the disclosure is the compound of Formula 4-1, wherein R'" is H, OH, NH2, Ci-3 alkyl, C1-3 alkylamino, C1-3 alkoxy or halogen, preferably H, F, methoxy, methylamino or dimethylamino.
- An embodiment of the disclosure is the compound of Formula 4, wherein k is 0, 1, 2 or 3, preferably 0, 1 or 2, more preferably 0 or 1.
- An embodiment of the disclosure is the compound of Formula 4, wherein U is S.
- An embodiment of the compound of Formula VI-1 is of the following Formula 16 or 17,
- An embodiment of the disclosure is the compound of Formula 16, wherein m2 is 1,
- An embodiment of the disclosure is the compound of Formula 16, wherein R 1 is [0329]
- An embodiment of the disclosure is the compound of Formula 16, wherein R' is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy, preferably H, halogen or C1-3 fluoroalkyl, more preferably H or F.
- An embodiment of the disclosure is the compound of Formula 16, wherein m is 0,
- An embodiment of the disclosure is the compound of Formula 16, wherein R" is H, halo, OH, NH2, Ci-3 alkoxy, C3-5 cycloalkyl, C3-5 cycloalkylamino or C1-3 alkylamino, preferably H, halo, methylamino, dimethylamino, cyclopropylamino or cyclopropyl, more preferably H, F or dimethylamino.
- An embodiment of the disclosure is the compound of Formula 16, wherein n is 0,
- An embodiment of the disclosure is the compound of Formula 16, wherein Z is C, U is O or S, W is CH.
- An embodiment of the disclosure is the compound of Formula 16, wherein Z is N, U is CH, W is CH
- An embodiment of the disclosure is the compound of Formula 16, wherein Z is C, U is CH, W is N.
- An embodiment of the disclosure is the compound of Formula 16, wherein R" is
- An embodiment of the disclosure is the compound of Formula 16, wherein k is 0,
- An embodiment of the disclosure is the compound of Formula 17, wherein m2 is 1, 2, 3, 4, 5 or 6, preferably 2 or 5.
- An embodiment of the disclosure is the compound of Formula 17, wherein R 1 is preferably NH.
- An embodiment of the disclosure is the compound of Formula 17, wherein R' is H, halogen, OH, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy, preferably H, halogen or C1-3 fluoroalkyl, more preferably H or F.
- An embodiment of the disclosure is the compound of Formula 17, wherein m is 0,
- An embodiment of the disclosure is the compound of Formula 17, wherein R" is H, halo, OH, NH2, Ci-3 alkoxy, C3-5 cycloalkyl, C3-5 cycloalkylamino or C1-3 alkylamino, preferably H, halo, methylamino, dimethylamino, cyclopropylamino or cyclopropyl, more preferably H, F or dimethylamino.
- An embodiment of the disclosure is the compound of Formula 17, wherein n is 0,
- An embodiment of the disclosure is the compound of Formula 17, wherein Z is C, U is O or S, W is CH.
- An embodiment of the disclosure is the compound of Formula 17, wherein Z is N, U is CH, W is CH
- An embodiment of the disclosure is the compound of Formula 17, wherein Z is C, U is CH, W is N.
- An embodiment of the disclosure is the compound of Formula 17, wherein R" is
- An embodiment of the disclosure is the compound of Formula 17, wherein k is 0,
- Some embodiments of the disclosure are the compounds having a structure depicted in Table 2, or a pharmaceutical acceptable salt, an enantiomer, a non-enantiomer, a tautomer, a racemate, a solvate, a metabolic precursor, a prodrug thereof.
- solvate, hydrate, salt, or ester of a compound of the present disclosure is provided herein.
- An aspect of the disclosure is a composition, comprising a compound disclosed herein and at least one pharmaceutically acceptable excipient.
- Ci-6 is intended to encompass Ci, C2, C3, C4, Cs, Ce, Ci-6, C1-5, C1-4, C1-3, C1-2, C2-6, C2-5, C2-4, C2-3, C3-6, C3-5, C3-4, C4-6, C4-5, and C5-6.
- Alkyl refers to a radical of a straight-chain or branched saturated hydrocarbon group having indicated number of carbon atoms.
- an alkyl group has 1 to 6 carbon atoms (“Ci-6 alkyl”).
- an alkyl group has 1 to 5 carbon atoms (“Ci-5 alkyl”).
- an alkyl group has 1 to 4 carbon atoms (“C1-4 alkyl”).
- an alkyl group has 1 to 3 carbon atoms (“C1-3 alkyl”).
- an alkyl group has 1 to 2 carbon atoms (“C1-2 alkyl”).
- an alkyl group has 1 carbon atom (“Ci alkyl”).
- an alkyl group has 2 to 6 carbon atoms (“C2-6 alkyl”).
- Ci-6 alkyl groups include methyl (Ci), ethyl (C2), «-propyl (C3), Ao-propyl (C3), «-butyl (C4), tert- butyl (C4), sec-butyl (C4), /.so-butyl (C4), «-pentyl (Cs), 3-pentyl (Cs), amyl (C5), neopentyl (Cs), 3 -methy 1-2-butyl (C5), tertiary amyl (C5), and «-hexyl (C6).
- alkenyl refers to an alkyl group with one or more carbon-carbon double bonds at any position of the chain, which can be monosub stituted or poly substituted, and can be monovalent, divalent or multivalent.
- alkenyl group include a vinyl group, a propenyl group, a butenyl group, a pentenyl group, a hexenyl group, a butadienyl group, a pentadienyl group, a hexadienyl group, etc.
- Alkynyl refers to an alkyl group with one or more carbon-carbon triple bonds at any position of the chain, which can be monosub stituted or poly sub stituted, and can be monovalent, divalent or multivalent.
- alkynyl groups include ethynyl, propynyl, butynyl, pentynyl, etc.
- Cycloalkyl includes any stable cyclic or polycyclic hydrocarbon group and any carbon atom which is saturated, which can be monosub stituted or polysubstituted, and can be monovalent, divalent or multivalent.
- Examples of such cycloalkyl groups include, but are not limited to, cyclopropyl, norbornyl, [2.2.2]bicyclooctane, [4.4.0]bicyclononane, etc.
- Substituted means that any one or more hydrogen atoms on a particular atom are replaced with substituents, including deuterium and hydrogen variants, as long as the valence of a particular atom is normal and the substituted compound is stable.
- substituents including deuterium and hydrogen variants, as long as the valence of a particular atom is normal and the substituted compound is stable.
- Ketone substitution does not occur on aromatic groups.
- optionally substituted means that it may or may not be substituted. Unless otherwise specified, the type and number of substituents may be arbitrary on the basis of being chemically achievable.
- any variable e.g., R
- its definition at each occurrence is independent of its definition at every other occurrence.
- R e.g., R
- said group may optionally be substituted by up to two R groups and R at each occurrence is selected independently from the definition of R.
- substituents and/or variables are permissible only if such combinations result in stable compounds.
- Alkoxy refers to refers to said alkyl group with a specified number of carbon atoms attached through an oxygen bridge. Unless otherwise specified, Ci-6 alkoxy includes Ci, Ci, Ci, C4, Cs and Ce alkoxy group. Examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, n-pentyloxy and S- pentyloxy.
- Aryl refers to a polyunsaturated, aromatic hydrocarbon substituent which can be monosub stituted or polysubstituted, and can be monovalent, divalent or polyvalent, and can be monocyclic or polycyclic (e.g., 1 to 3 rings; at least one of which is aromatic). They are fused together or covalently linked.
- Halo or "halogen” by itself or as part of another substituent refers to a fluorine, chlorine, bromine or iodine atom.
- Haloalkyl includes both monohaloalkyl and polyhaloalkyl.
- halo(Ci-4)alkyl includes, but is not limited to, trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, etc.
- examples of haloalkyl include, but are not limited to, trifluoromethyl, trichloromethyl, pentafluoroethyl, and pentachloroethyl.
- Heterocyclo refers to a radical of a 3 - to 10-membered non-aromatic ring or aromatic ring system having indicated ring carbon atoms (such as 2 to 6 ring carbon atoms) and 1 to 4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen and sulfur (“C2-6 heterocyclo”).
- C2-6 heterocyclo nitrogen, oxygen and sulfur
- a heterocyclo group can either be monocyclic (“monocyclic heterocyclo”) or a fused, bridged or spiro ring system such as a bicyclic system (“bicyclic heterocyclo”), and can be saturated or partially unsaturated.
- Heterocyclo bicyclic ring systems can include one or more heteroatoms in one or both rings.
- “Heterocyclo” also includes ring systems wherein the heterocyclic ring, as defined above, is fused with one or more carbocyclic groups wherein the point of attachment is either on the carbocyclic or heterocyclic ring, or ring systems wherein the heterocyclic ring, as defined above, is fused with one or more aryl or heteroaryl groups, wherein the point of attachment is on the heterocyclic ring, and in such instances, the number of ring members continue to designate the number of ring members in the heterocyclic ring system.
- Nitrogen protecting group refers to a protecting group for preventing side reactions at the amino nitrogen position.
- Representative amino protecting groups include, but are not limited to formyl; acyl, such as alkanoyl (e.g., acetyl, trichloroacetyl or trifluoroacetyl); alkoxycarbonyl, such as tert-butoxycarbonyl (Boc); Arylmethoxycarbonyl, such as benzyloxycarbonyl (Cbz) and 9-fluorenylmethoxycarbonyl (Fmoc); arylmethyl, such as benzyl (Bn), trityl (Tr), 1, 1-di -(4'-methoxyphenyl)methyl; silyl groups such as trimethyl silyl (TMS) and tert-butyldimethylsilyl (TBS), etc..
- acyl such as alkanoyl (e.g., acetyl,
- a heterocyclo group is a 5-10 membered non-aromatic ring system or aromatic ring system having indicated ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur.
- a heterocyclo group is a 5-6 membered non-aromatic ring system or aromatic ring system having indicated ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-6 membered heterocyclo”).
- the 5-6 membered heterocyclo has 1-3 ring heteroatoms selected from nitrogen, oxygen, and sulfur.
- the 5-6 membered heterocyclo has 1-2 ring heteroatoms selected from nitrogen, oxygen, and sulfur.
- the 5-6 membered heterocyclo has one ring heteroatom selected from nitrogen, oxygen, and sulfur.
- Exemplary 3-membered heterocyclo groups containing one heteroatom include, without limitation, azirdinyl, oxiranyl, and thiorenyl.
- Exemplary 4-membered heterocyclo groups containing one heteroatom include, without limitation, azetidinyl, oxetanyl, and thietanyl.
- Exemplary 5-membered heterocyclo groups containing one heteroatom include, without limitation, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, pyrrolidinyl, dihydropyrrolyl, and pyrrolyl-2,5-dione.
- 5-membered heterocyclo groups containing two heteroatoms include, without limitation, dioxolanyl, oxasulfuranyl, disulfuranyl, and oxazolidin-2-one.
- Exemplary 5-membered heterocyclo groups containing three heteroatoms include, without limitation, triazolinyl, oxadiazolinyl, and thiadiazolinyl.
- Exemplary 6-membered heterocyclo groups containing one heteroatom include, without limitation, piperidinyl, tetrahydropyranyl, dihydropyridinyl, and thianyl.
- Exemplary 6-membered heterocyclo groups containing two heteroatoms include, without limitation, piperazinyl, morpholinyl, dithianyl, and dioxanyl.
- 6-membered heterocyclo groups containing two heteroatoms include, without limitation, triazinanyl.
- Exemplary 7-membered heterocyclo groups containing one heteroatom include, without limitation, azepanyl, oxepanyl, and thiepanyl.
- Exemplary 8-membered heterocyclo groups containing one heteroatom include, without limitation, azocanyl, oxecanyl, and thiocanyl.
- Exemplary 5-membered heterocyclo groups fused to a Cr, aryl ring include, without limitation, indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl, benzoxazolinonyl, and the like.
- Exemplary 6-membered heterocyclo groups fused to an aryl ring include, without limitation, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and the like.
- pharmaceutically acceptable salt means a salt that is not harmful to mammals, especially humans.
- Pharmaceutically acceptable salts can be formed using non-toxic acids or bases, including mineral acids or inorganic bases, or organic acids or organic bases.
- examples of pharmaceutically acceptable salts include metal salts formed with aluminum, calcium, lithium, magnesium, potassium, sodium, zinc and so on, and organic salts formed with lysine, N, N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine), procaine and so on.
- pharmaceutically acceptable salts contain acid-addition salts and base-addition salts.
- solvate means a solvent-containing compound that is formed by association of one or a plurality of solvent molecules to the compounds of the present disclosure.
- Solvates include, for example, monosolvates, disolvates, trisolvates, and tetrasolvates.
- solvates include hydrates.
- hydrate means a compound further containing a stoichiometric or a non-stoichiometric amount of water constrained by non-covalent bonding intermolecular force, or a salt thereof. Hydrates include monohydrates, dihydrates, trihydrates, tetrahydrates, and the like.
- a “subject” to which administration is contemplated includes, but is not limited to, humans (i.e., a male or female of any age group, e g., a pediatric subject (e.g., infant, child, adolescent) or adult subject (e.g., young adult, middle-aged adult, or senior adult)) and/or other non-human animals, for example, mammals (e.g., primates (e.g., cynomolgus monkeys, rhesus monkeys); commercially relevant mammals such as cattle, pigs, horses, sheep, goats, cats, and/or dogs) and birds (e.g., commercially relevant birds such as chickens, ducks, geese, and/or turkeys).
- the animal is a mammal.
- the animal may be a male or female and at any stage of development.
- a non-human animal may be a transgenic animal.
- administer refers to implanting, absorbing, ingesting, injecting, inhaling, or otherwise introducing an inventive compound, or a pharmaceutical composition thereof.
- treatment refers to reversing, alleviating, delaying the onset of, or inhibiting the progress of a “pathological condition” (e.g., a disease, disorder, or condition, or one or more signs or symptoms thereof) described herein.
- pathological condition e.g., a disease, disorder, or condition, or one or more signs or symptoms thereof
- treatment may be administered after one or more signs or symptoms of the disease have developed or have been observed. In other embodiments, treatment may be administered in the absence of signs or symptoms of the disease or condition.
- treatment may be administered to a susceptible subj ect prior to the onset of symptoms (e.g., in light of a history of symptoms and/or in light of genetic or other susceptibility factors). Treatment may also be continued after symptoms have resolved, for example, to delay or prevent recurrence.
- an “effective amount” of a compound or a composition refers to an amount sufficient to elicit the desired biological response, i.e., treating the condition.
- the effective amount of a compound or a composition may vary depending on such factors as the desired biological endpoint, the pharmacokinetics of the compound, the condition being treated, the mode of administration, and the age and health of the subject.
- An effective amount encompasses therapeutic and prophylactic treatment.
- a “therapeutically effective amount” of a compound or a composition is an amount sufficient to provide a therapeutic benefit in the treatment of a condition or to delay or minimize one or more symptoms associated with the condition.
- a therapeutically effective amount of a compound or a composition means an amount of therapeutic agent, alone or in combination with other therapies, which provides a therapeutic benefit in the treatment of the condition.
- the term “therapeutically effective amount” can encompass an amount that improves overall therapy, reduces, or avoids symptoms or causes of the condition, or enhances the therapeutic efficacy of another therapeutic agent.
- alpha-synuclein refers to a 140 amino acid polypeptide with the following amino acid sequence (wild-type human a-synuclein).
- binder refers to a compound that binds to a protein.
- the binder binds to a protein with a Kd of less than 50,000 nM, less than 20,000 nM, less than 10,000 nM, less than 5,000 nM, less than 2,500 nM, less than 1,000 nM, less than 900 nM, less than 800 nM, less than 700 nM, less than 600 nM, less than 500 nM, less than 400 nM, less than 300 nM, less than 200 nM, less than 100 nM, less than 90 nM, less than 80 nM, less than 70 nM, less than 60 nM, less than 50 nM, less than 40 nM, less than 30 nM, less than 20 nM, less than 10 nM, less than 5 nM, less than 4 nM, less than 3 nM, less than 2 nM, or less than 1 nM.
- proteasome refers to a protease complex for carrying out degradation of proteins.
- the proteasome is a multisubunit enzyme complex, which can also play a key role regulating proteins that control cell-cycle progression and apoptosis.
- the proteasome conducts proteolysis of selected proteins.
- pharmaceutically acceptable excipient means pharmaceutically acceptable materials, compositions, or vehicles such as physiological saline solutions, liquid or solid fillers, diluents, solvents, or encapsulants.
- pharmaceutically acceptable excipients include water, saline water, physiological saline water or phosphate buffered saline water (PBS), sodium chloride injection solution, Ringer’s injection solution, isotonic dextrose injection solution, sterile water injection solution, dextrose, and lactated Ringer’s injection solution.
- Another aspect of the present disclosure is a method for aiding in the treatment of a synucleinopathy in a subject, the method comprising, consisting essentially of, or consisting of administering to the subject an effective amount of a compound as disclosed herein, or a composition as disclosed herein.
- Another aspect of the present disclosure is a method of treating a subject (e.g., a human) suffering from a disease characterized by the presence of Lewy bodies or pathological aggregates of a-synuclein, the method comprising, consisting essentially of, or consisting of administering to the subject an effective amount of a compound as disclosed herein or a composition as disclosed herein.
- a subject e.g., a human
- Another aspect of the present disclosure is a method for prophylaxis of a disease characterized by the presence of Lewy bodies or pathological aggregates of a-synuclein in a subject, the method comprising, consisting essentially of, or consisting of administering to the subject an effective amount of a compound or a composition as disclosed herein.
- kits for treating a disease characterized by the presence of Lewy bodies or pathological aggregates of a-synuclein in a subject comprising, consisting essentially of, or consisting of administering to the subject an effective amount of a compound or a pharmaceutical composition described herein.
- kits for lessening the severity of a disease characterized by the presence of Lewy bodies or pathological aggregates of a-synuclein in a subject comprising, consisting essentially of, or consisting of administering to the subject an effective amount of a compound or a pharmaceutical composition described herein.
- kits for delaying the progression of a disease characterized by the presence of Lewy bodies or pathological aggregates of a-synuclein in a subject comprising, consisting essentially of, or consisting of administering to the subject an effective amount of a compound or a pharmaceutical composition described herein.
- kits for reducing the risk of developing a disease characterized by the presence of Lewy bodies or pathological aggregates of a-synuclein in a subject comprising, consisting essentially of, or consisting of administering to the subject at risk of developing the disease an effective amount of a compound or a pharmaceutical composition described herein.
- kits for delaying the onset of a disease characterized by the presence of Lewy bodies or pathological aggregates of a-synuclein in a subject at risk of developing the disease comprising, consisting essentially of, or consisting of administering to the subject an effective amount of a compound or a pharmaceutical composition described herein.
- the subject to be treated exhibits one or more symptoms (signs) of synucleinopathies, such as neuropsychiatric manifestations (depression, dementia, hallucinations, anxiety, apathy, anhedonia), autonomic changes (orthostatic hypotension, bladder disturbances, constipation, fecal incontinence, sialorrhea, dysphagia, sexual dysfunction, changes in cerebral blood flow), sensory changes (olfactory, pain, color discrimination abnormal sensations), sleep disorders (REM sleep behavior disorder (RBD), restless legs syndrome/periodic extremity movements, hypersomnia, insomnia), or other signs and symptoms (fatigue, diplopia, blurred vision, seborrhea, weight loss/gain).
- neuropsychiatric manifestations depression, dementia, hallucinations, anxiety, apathy, anhedonia
- autonomic changes orthostatic hypotension, bladder disturbances, constipation, fecal incontinence, sialorrhea, dysphagia, sexual dysfunction, changes in
- the subject to be treated does not exhibit one or more symptoms of a synucleinopathy, but is known to have a genetic risk for developing a disease characterized by the presence of Lewy bodies or pathological aggregates of a-synuclein in the brain.
- a genetic risk for developing a disease characterized by the presence of Lewy bodies or pathological aggregates of a-synuclein in the brain.
- such an individual may have one or more relatives with the disease, or their risk is determined by analysis of genetic or biochemical markers.
- mutations in SNCA PARK1, encoding a-synuclein
- A30P, E46K, H50Q, G51D, and A53T mutations in SNCA (PARK1, encoding a-synuclein), including A30P, E46K, H50Q, G51D, and A53T, as well as duplications and triplications of the entire SNCA gene cause autosomal dominant forms of PD.
- PINK1 PARK6, PTEN-induced kinase 1
- DJ-1 PARK7
- Parkin PARK2
- ATP13A2 PARK9, ATPase type 13A2
- FBX07 PARK 15, F-box only protein 7
- PLA2 GB PARK14, phospholipase A2, group VI
- 28 different genetic risk loci associated with PD and related synucleinopathies have been identified including SNCA, LRRK2, GBA/SYT11, MAPT, HLA-DRB5, GAK, GCH1, NUCKS1/RAB7L1, SLC41A1, BST1, SIPA1L2,
- ACM SD/TMEM 163, STK39, MCCC1, TMEM 175/GAK/DGKQ, FAM47E/SCARB2, GPNMB, FGF20, INPP5F, MIR4697, CCDC62, GCH1, VPS13C, BCKDK/STX1B, SREBF/RAIl, RIT2 and DDRGK1 (Nails et al. (2014) Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nature Genetics 46(9): 989-993).
- the antibodies described herein, or pharmaceutical compositions comprising the same are administered to a patient susceptible to, or otherwise at risk of the disease in a regime (dose, frequency and route of administration) effective to reduce the risk, lessen the severity, or delay the onset of at least one sign or symptom of the disease.
- a regime dose, frequency and route of administration
- the regime is effective to inhibit or delay accumulation of a-synuclein in the brain, and/or inhibit or delay its toxic effects and/or inhibit or delay development of behavioral deficits in the patient.
- the methods described above generate a beneficial therapeutic response in a patient (e.g., reduction of a-synuclein aggregates in the brain, improved cognitive function, and/or reversing, treating or preventing cognitive decline) in the subject.
- the compounds or the pharmaceutical compositions described herein are administered to a patient suspected of, or already suffering from a disease characterized by the presence of Lewy bodies or pathological aggregates of a-synuclein in a regime (dose, frequency and route of administration) effective to ameliorate or at least inhibit further deterioration of at least one sign or symptom of the disease.
- the regime is effective to reduce or at least inhibit further increase of levels of a-synuclein, associated toxicities, and/or behavioral deficits.
- the treatments can result in, e.g., a reduction of a-synuclein aggregates in the brain by 10% or more, 20% or more, 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, or 90% or more, relative to before initiating treatment or as compared to a population of untreated control patients.
- the disease characterized by the presence of Lewy bodies or pathological aggregates of a-synuclein in the brain is Parkinson's disease (including idiopathic Parkinson's disease), DLB, DLBD, LBVAD, pure autonomic failure, Lewy body dysphagia, incidental LBD, inherited LBD (e.g., mutations of SNCA (PARKl), LRRK2 (PARK8), VP S35 (PARK 17), PINK1 (PARK6), DJ-1 (PARK7), Parkin (PARK2), ATP13A2 (PARK9), FBX07 (PARK 15) and PLA2 GB (PARK 14)), or multiple system atrophy (MSA; e.g., olivopontocerebellar atrophy, striatonigral degeneration and Shy-Drageri syndrome).
- MSA multiple system atrophy
- compositions of the present disclosure can be administered to humans and other animals orally, parenterally, intracisternally, intraperitoneally, intrathecally, intraventricularly, topically, bucally, or the like, depending on the disease or condition being treated.
- a pharmaceutical composition comprising a compound of the disclosure is administered orally or parenterally, at dosage levels sufficient to deliver from about 0.001 mg/kg to about 200 mg/kg in one or more doses for one or several days.
- the effective amount per dose varies from about 0.001 mg/kg to about 200 mg/kg, about 0.001 mg/kg to about 100 mg/kg, about 0.01 mg/kg to about 100 mg/kg, from about 0.01 mg/kg to about 50 mg/kg, from about 0.1 mg/kg to about 40 mg/kg, from about 0.5 mg/kg to about 30 mg/kg, from about 0.01 mg/kg to about 10 mg/kg, from about 0.1 mg/kg to about 10 mg/kg, of subject body weight per day, one or more times a day, to obtain the desired therapeutic and/or prophylactic effect.
- the compounds described herein are at dosages sufficient to deliver from about 0.001 mg/kg to about 200 mg/kg, from about 0.001 mg/kg to about 100 mg/kg, from about 0.01 mg/kg to about 100 mg/kg, from about 0.01 mg/kg to about 50 mg/kg, from about 0.1 mg/kg to about 40 mg/kg, from about 0.5 mg/kg to about 30 mg/kg, from about 0.01 mg/kg to about 10 mg/kg, from about 0.1 mg/kg to about 10 mg/kg, or from about 1 mg/kg to about 25 mg/kg, of subj ect body weight per day, one or more times a day, to obtain the desired therapeutic and/or prophylactic effect.
- the desired dosage may be delivered three times a day, twice a day, once a day, every other day, every third day, every week, every two weeks, every three weeks, or every four weeks.
- the dosage is delivered using multiple administrations (e.g., two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, or more administrations).
- the composition described herein is administered at a dose that is below the dose at which the agent causes non-specific effects.
- compositions described herein can be prepared by methods generally known in the art of pharmacology. In general, such methods include the steps of combining the compound of the disclosure with a carrier and/or one or more other accessory ingredients, and then shaping and/or packaging the product into a desired single- or multi-dose unit.
- compositions can be prepared, packaged, and/or sold in bulk, as a single unit dose, and/or as a plurality of single unit doses.
- a “unit dose” is a discrete amount of the pharmaceutical composition comprising a predetermined amount of the active ingredient.
- the amount of the active ingredient is generally equal to the dosage of the active ingredient which would be administered to a subject and/or a convenient fraction of such a dosage, such as, for example, one-half or one-third of such a dosage.
- compositions include inert diluents, dispersing and/or granulating agents, surface active agents and/or emulsifiers, disintegrating agents, binding agents, preservatives, stabilizers, buffering agents, lubricating agents, and/or oils. Excipients such as cocoa butter and suppository waxes, coloring agents, coating agents, sweetening, flavoring, and perfuming agents may also be present in the composition.
- Suitable diluents include calcium carbonate, sodium carbonate, calcium phosphate, calcium phosphate, calcium sulfate, calcium hydrogen phosphate, sodium phosphate lactose, sucrose, cellulose, microcrystalline cellulose, kaolin, mannitol, sorbitol, inositol, sodium chloride, dry starch, cornstarch, powdered sugar, and mixtures thereof.
- Suitable granulating and/or dispersing agents include potato starch, corn starch, tapioca starch, sodium starch glycolate, clays, alginic acid, guar gum, citrus pulp, agar, bentonite, cellulose, and wood products, natural sponge, cation-exchange resins, calcium carbonate, silicates, sodium carbonate, cross-linked poly(vinyl-pyrrolidone) (crospovidone), sodium carboxymethyl starch (sodium starch glycolate), carboxymethyl cellulose, cross-linked sodium carboxymethyl cellulose (croscarmellose), methylcellulose, pregelatinized starch (starch 1500), microcrystalline starch, water insoluble starch, calcium carboxymethyl cellulose, magnesium aluminum silicate
- LCMS measurement was run on an Agilent 1200 HPLC/6100 SQ System using the following conditions: Method A: Mobile Phase: A: Water (0.01% TFA) B: CAN (0.01% TFA); Gradient Phase: 5%B increasing to 95%B within 1.4 min, 95%B with 1.6 min (total runtime: 3 min); Flow Rate: 2.3 mL/min; Column: SunFire C18, 4.6*50 mm, 3.5 pm; Column Temperature: 50°C. Detectors: ADC ELSD, DAD (214 nm and 254 nm), ES-API.
- Method B Mobile Phase: A: Water (10 mMNFEHCCri) B: Acetonitrile; Gradient Phase: 5% to 95%B within 1.5 min, 95%B with 1.5 min (total runtime: 3 min); Flow Rate: 2.0 mL/min; Column: XBridge C18, 4.6*50 mm, 3.5 pm; Column Temperature: 40°C. Detectors: ADC ELSD, DAD (214 nm and 254 nm), MSD (ES-API).
- Method C Mobile Phase: A: Water (10 mM H4HC03)B: Acetonitrile; Gradient Phase: 5% to 95%B within 1.5 min, 95%B with 1.5 min (total runtime: 3 min); Flow Rate: 2.0 mL/min; Column: XBridge C18, 4.6*50mm, 3.5 pm; Column Temperature: 40°C. Detectors: ADC ELSD, DAD (214 nm and 254 nm), MSD (ES-API).
- N-[2-[4-[6-(dimethylamino)pyridin-3-yl]phenyl]-l,3-benzothiazol-6-yl]carbamate 500 mg, 1.12 mmol
- DMF 10 mL
- NaFI 107.49 mg, 4.48 mmol
- Compound 161409 could be synthesized by method similar to example 19.
- Compound 164263 A mixture of tert-butyl N-(2-bromanyl-l,3-benzothiazol-6-yl)carbamate (1100 mg, 3.34 mmol), N,N-dimethyl-5-[4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-3-(trifluoromethyl )phenyl]pyridin-2-amine (1704 mg, 4.34 mmol), Pd(dppf)Ch (247 mg, 0.33 mmol) and 2M Na2CC>3(aq) solution (5 mL, 10.02 mmol) in dioxane (35 mL) was heated at 80°C for 16 h under argon.
- N-[2-[4-[6-(dimethylamino)pyridin-3-yl]-2-(trifluoromethyl)phenyl]-l,3-benzothiazol-6-yl] carbamate (1056 mg, 2.05 mmol) in DMF (20 mL) was added NaH (148 mg, 6.16 mmol) at 0°C and stirred at 25°C for 1 h.
- 2-[2-(4-methylphenyl)sulfonyloxyethoxy]ethyl 4-methylbenzenesulfonate (2.55 g, 6.16 mmol) in DMF (20 mL) was added to the reaction mixture and stirred at room temperature for 14 h.
- N-[4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2-yl]carbamate (1.52 g, 4.75 mmol)
- 2-(4-bromophenyl)-6-methoxy-imidazo[l,2-a]pyridine 1.2 g, 3.96 mmol
- triphenylphosphine (34.6 mg, 0.13 mmol) in EtOH (4 mL) and toluene (2.8 mL) was purged with argon and then added with K2CO3 solution (1.75M, 7.92 mL, 13.85 mmol) dropwise.
- N-[2-[2-(2-iodanylethoxy)ethoxy]ethyl]-N-[4-[4-(6-methoxyimidazo[l,2-a]pyri din-2 -yl)phe nyl]pyridin-2-yl]carbamate 100 mg, 0.15 mmol
- K2CO3 63 mg, 0.46 mmol
- methyl 5-azanyl-5-oxidanylidene-4-(6-oxidanyl-3-oxidanylidene-lH-isoindol-2-yl)pentanoate 49 mg, 0.17 mmol
- DMF 5 mL
- N-methyl-N-[5-[4-[6-[(2-methylpropan-2-yl)oxycarbonylamino]-l,3-benzothiazol-2-yl]-3-(t rifluoromethyl)phenyl]pyridin-2-yl]carbamate 200 mg, 0.33 mmol
- dry DMF 5 mL
- NaH 40 mg, 1.00 mmol
- N-[2-[4-[6-(dimethylamino)pyridin-3-yl]-2-(trifluoromethyl)phenyl]-l,3-benzothiazol-6-yl] carbamate (447 mg, 0.87 mmol) in DMF (8 mL) was added NaH (63 mg, 2.61 mmol) at 0°C, stirred at room temperature for 1 h and then added 5-(4-methylphenyl)sulfonyloxypentyl
- N-[2-[4-[6-(dimethylamino)pyridin-3-yl]-2-(trifluoromethyl)phenyl]-l,3-benzothiazol-6-yl] carbamate 300 mg, 0.58 mmol) in DMF (5 mL) was cooled to 0°C and added NaH (56 mg, 2.33 mmol). The mixture was stirred at room temperature for 1 h, added 2-azidoethyl 4-methylbenzenesulfonate (281 mg, 1.17 mmol) in DMF (5 mL) and heated at 50°C for 20 h. The mixture was cooled to 0°C and added water (5 mL).
- N-(2-azidoethyl)-N-[2-[4-[6-(dimethylamino)pyridin-3-yl]-2-(trifluoromethyl)phenyl]-l,3-b enzothiazol-6-yl]carbamate (341 mg, 0.58 mmol) in THF (5mL)/EtOH (5mL) was added Pd(OH)2 (1701 mg, 1.61 mmol) and stirred under 1 atmosphere of Lb for 4 h. The mixture was filtered through a Celite pad and the filtrate was concentrated to dryness.
- the supernatant was then boiled at 95 °C for 15 min with manual agitation by every 5 minutes, followed by centrifugation (6000 g, 30 min, 4 °C).
- Supernatant was dialyzed with (10 mM Tris, 1 mM EGTA, 50 mMNaCl, pH 7.5) buffer and concentrated with concentrator.
- the collected sample was loaded onto a Superdex200 column, the flow-through fraction was then loaded onto a Q-HP column. Collected fractions with a-synuclein eluates were pooled, concentrated and stored at -80 °C.
- ReNcell VM a-synuclein aggregation assay was conducted at Charles River Laboratories (CRL).
- ReNcell VM is an immortalized human neural progenitor cell line derived from the ventral mesencephalon region of the brain.
- ReNcell VM cells were selected as in vitro cellular model for the a-synuclein aggregation assay, based on their growth features, differentiation potential into terminally differentiated neurons and amenability to adenoviral transduction. Aggregated human wild type a-synuclein was overexpressed through adenoviral delivery.
- Aggregated a-synuclein was detected with the aggregate-selective anti-a-synuclein antibody MJFR14 using immunocytochemistry; total a-synuclein levels were detected with Syn205 (a/b-synuclein-specific antibody).
- the ReNcell VM a-synuclein aggregation assay was applied for compound screening to identify compounds capable of degrading a-synuclein aggregates. Specifically, adenovirally transduced ReNcell VM cells were treated with test compounds (serially diluted) for 24 hours, followed by fixation, and then processed for ReNcell immunocytochemistry by staining with Syn205 and MJFR14.
- Immunoreactivity toward aggregated (MJFR14) and total a-synuclein (Syn205) was quantified using high content-based segmentation of immunoactive areas in immunocytochemical images (performed with the IN Cell 2200 (GE Healthcare)), followed by quantification of immunofluorescent intensity (performed by CRL’s developed algorithm using IN Cell Developer Toolbox software).
- FIG. 1 shows the high content-based quantifications of aggregated a-synuclein species in combination with determination of nuclei count (% remaining cells) in differentiated ReNcell VM cells. Results showed that 24 hour treatment with test compounds 166362, 170357, 162640 and 180948, respectively, induced a concentration-dependent inhibition of MJFR14 immunoreactivity, indicative of decreased a-synuclein aggregation. Each panel of graph displays normalized data for percentage effect (PE) and remaining cells (%).
- Percentage effect (PE) Inhibition in comparison to BLANK (0.1% DMSO).
- PE 100 - (signal of compound/average signal BLANK) x 100 [0561] Compound-induced cytotoxicity (% remaining cells)
- % remaining cells (nuclei count of compound/average nuclei count of BLANK) x 100
- FIGS 2A-2D show the representative immunocytochemical images of cells treated with vehicle (0.1% DMSO) and test compounds 132168, 166362, and 170357, and immunostained with MJFR14, illustrating the reduction in a-synuclein expression following treatment with compounds 132168 and 166362.
- DC50 indicates the concentration at which 50% of a-synuclein aggregates has been degraded.
- Example 40 In Vivo Assay For Degrading a-Synuclein Ag2regates
- mice Male transgenic Line61 mice at age of three-month-old were used for the study. Mice were treated once via intravenous injection with the compound 132168 (25 mpk). Plasma and brain samples were collected at 0.25, 0.5, 1, 2, 4, 8 and 24 h post treatment. Blood samples were collected via cardiac puncture into MiniCollect® 0.5 mL K2EDTA (Potassium ethylenediaminetetraacetic acid) tubes. The blood samples were centrifuged at 3000 x g for 10 minutes at room temperature (22°C). Plasma was transferred to a pre-labeled 1.5 ml LoBind Eppendorf tube (2 aliquot, each ⁇ 75 m ⁇ ), frozen on dry ice and stored at -80°C until analysis.
- K2EDTA Paratassium ethylenediaminetetraacetic acid
- example compound 132168 was administered to mice in a pharmacokinetic study (10 and 25 mg/kg, intravenous).
- Animal Husbandry Mice were housed at animal room environment with ventilation 15 times/hour, lighting 12 hours/day, temperature 20 °C to 24 °C and humidity 40 % to 70 %. The study rooms were disinfected and cleaned prior to the start of the study and the operation area was cleaned after each dosing or sampling during the study conduct. All animals had free access to food and water during the study. The animals had access to Certified Rodent Diet and water ad libitum. The nutritional composition and levels of contaminants of the diet and impurities and contaminants of the water were monitored by third organization. The health status of the animals was evaluated in accordance with accepted animal husbandry procedures and deemed suitable for experimental use.
- Sample Collection & Processing Approximately 110 pL of whole blood were collected from all animals via facial or cardiac puncture under anesthesia with Isoflurane into test tubes containing potassium ethylenediaminetetraacetate (K2EDTA) at 0.25, 0.5, 1, 2, 4, 8 and 24 hr post dose. Brian samples were collected at 0.25, 0.5, 1, 2, 4, 8 and 24 hours post dose. A perfusion with pre-cold saline will be conducted via cardiac puncture before brain collection. Blood samples were centrifuged at 2000g at 4°C for 5 minutes to obtain plasma samples by transferring the supernatants into new tubes. All plasma and brain samples were stored at approximately -70 °C until analysis.
- K2EDTA potassium ethylenediaminetetraacetate
- Bioanalytical Method Development The concentrations of compound in plasma and brain samples were determined using a liquid chromatography with tandem mass spectrometry (LC-MS/MS) based method.
- Embodiment 1 A method to treat synucleinopathy in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of Formula A,
- EBM is an E3 ubiquitin ligase binding moiety
- L is a linker covalently attached to EBM and TBM; and SBM is an a-synuclein protein binding moiety of the formula: or a pharmaceutical acceptable salt, an enantiomer, a non-enantiomer, a tautomer, a racemate, a solvate, a metabolic precursor, a prodrug thereof, wherein is covalently linked to L; and is a substituted or unsubstituted bicyclic fused aromatic ring containing at least 1 ring heteroatom selected from O, S, and N; is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; and is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; or is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S,
- Embodiment 2 A method to reduce a-synuclein aggregation in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of Formula A,
- EBM is an E3 ubiquitin ligase binding moiety
- L is a linker covalently attached to EBM and TBM; and SBM is an a-synuclein protein binding moiety of the formula: or a pharmaceutical acceptable salt, an enantiomer, a non-enantiomer, a tautomer, a racemate, a solvate, a metabolic precursor, a prodrug thereof, wherein is covalently linked to L; and is a substituted or unsubstituted bicyclic fused aromatic ring containing at least 1 ring heteroatom selected from O, S, and N; is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; and is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; or is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S,
- Embodiment 3 A method to reduce Lewy bodies in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of Formula A,
- EBM is an E3 ubiquitin ligase binding moiety
- L is a linker covalently attached to EBM and TBM; and SBM is an a-synuclein protein binding moiety of the formula: or a pharmaceutical acceptable salt, an enantiomer, a non-enantiomer, a tautomer, a racemate, a solvate, a metabolic precursor, a prodrug thereof, wherein is covalently linked to L; and is a substituted or unsubstituted bicyclic fused aromatic ring containing at least 1 ring heteroatom selected from O, S, and N; is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; and is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; or is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S,
- Embodiment 4 Use of a compound of Formula A:
- EBM-L-SBM (Formula A) or a pharmaceutical acceptable salt, a enantiomer, a non-enantiomer, a tautomer, a racemate, a solvate, a metabolic precursor, or a prodrug thereof, in the manufacture of a medicament for treating synucleinopathy, wherein
- EBM is an E3 ubiquitin ligase binding moiety
- L is a linker covalently attached to EBM and TBM; and SBM is an a-synuclein protein binding moiety of the formula: wherein covalently linked to L, and is a substituted or unsubstituted bicyclic fused aromatic ring containing at least 1 ring heteroatom selected from O, S, and N; is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; and is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; or is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; is a substituted or unsubstituted mono
- Embodiment 5 Use of a compound of Formula A:
- EBM-L-SBM (Formula A) or a pharmaceutical acceptable salt, a enantiomer, a non-enantiomer, a tautomer, a racemate, a solvate, a metabolic precursor, or a prodrug thereof, in the manufacture of a medicament for reducing a-synuclein aggregation, wherein
- EBM is an E3 ubiquitin ligase binding moiety
- L is a linker covalently attached to EBM and TBM; and SBM is an a-synuclein protein binding moiety of the formula: wherein is covalently linked to L; and is a substituted or unsubstituted bicyclic fused aromatic ring containing at least 1 ring heteroatom selected from O, S, and N; is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; and is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; or is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; is a substituted or unsubstituted
- Embodiment 6 Use of a compound of Formula A:
- EBM-L-SBM (Formula A) or a pharmaceutical acceptable salt, a enantiomer, a non-enantiomer, a tautomer, a racemate, a solvate, a metabolic precursor, or a prodrug thereof, in the manufacture of a medicament for reducing Lewy bodies, wherein
- EBM is an E3 ubiquitin ligase binding moiety
- L is a linker covalently attached to EBM and TBM; and SBM is an a-synuclein protein binding moiety of the formula: wherein is covalently linked to L; and is a substituted or unsubstituted bicyclic fused aromatic ring containing at least 1 ring heteroatom selected from O, S, and N; is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; and is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; or is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; is a substituted or unsubstituted monocyclic aromatic ring containing 0 to 2 ring heteroatoms selected from O, S, and N; is a substituted or unsubstituted
- Embodiment 7 The method of Embodiment 1 or the use of Embodiment 4, wherein the synucleinopathy is Parkinson’s Disease (PD), dementia with Lewy bodies (DLB), multiple system atrophy (MSA), or a combination of two or more thereof
- Embodiment 8 The method or use of any one of Embodiments 1-7, wherein the substituted or unsubstituted bicyclic fused aromatic ring is a substituted or unsubstituted bicyclic 5-6 system.
- Embodiment 9 The method or use of any one of Embodiments 1-8, wherein SBM is of Formula B or Formula C wherein
- Z is C or N; U is O, S or CH; V is N or Mi;
- Embodiment 10 The method or use of any one of Embodiments 1-9, wherein EBM is wherein
- R 3 is H or Ci-6 alkyl; each occurrence of R 2 is independently selected from the group consisting of H, OH, Ci-6 alkyl, Ci-6 alkoxy, Ci-6 alkylamino andMB; m6 is 0, 1, 2, 3 or 4; and
- Embodiment 11 The method or use of any one of Embodiments 1-10, wherein the compound is of any one of Formula I to Formula YI,
- Z is C or N; U is O, S or CH;
- J is CR 6 or N;
- X is CR 6 or N;
- Y is CR 6 or N; where at least one of J, X and Y is N, but J and Y are not N at the same time, X and Y are not N at the same time;
- R 6 is independently selected from the group consisting of H, NH2, Ci-6 alkyl and Ci-6 alkoxy, wherein NH2, Ci-6 alkyl or Ci-6 alkoxy is optionally substituted by 1 to 3 of C1-3 alkyl, C3-6 cycloalkyl and/or halo; in Formula I, L3 is a bond, -NR-, -0-, or -S-, wherein R is hydrogen, optionally substituted acyl, optionally substituted alkyl or a nitrogen protecting group; R 3 is H or Ci- 6 alkyl; Yi is CH2 or V is N, where Z and U are not heteroatoms at the same time; in Formula II, each occurrence of R 2 is independently selected from the group consisting of H, OH, Ci-6 alkyl, Ci-6 alkoxy, Ci-6 alkylamino and NH2; m6 is 0, 1, 2, 3 or 4;
- Yi is CH2 or V is N, where Z and U are not heteroatoms at the same time; in Formula III, V is N, where Z and U are not heteroatoms at the same time; in Formula IV, L3 is a bond, -NR-, -0-, or -S-, wherein R is hydrogen, optionally substituted acyl, optionally substituted alkyl or a nitrogen protecting group; R 3 is H or Ci-6 alkyl; two of U, Z, V and T contain heteroatoms; in Formula V, each occurrence of R 2 is independently selected from the group consisting of H, OH, Ci-6 alkyl, Ci-6 alkoxy, Ci-6 alkylamino and NH2; m6 is 0, 1, 2, 3 or 4; two of U, Z, V and T contain heteroatoms; in Formula VI, V is N; T is CH or N; where up to two of U, Z, V and T contain heteroatoms.
- Embodiment 14 The method or use of Embodiment 11, wherein L2 is selected from the group consisting of substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, substituted or unsubstituted heteroaryl ene, or substituted or unsubstituted heteroalkylene, and combinations thereof; preferably, L2 is selected from the group consisting of substituted and unsubstituted alkylene, substituted and unsubstituted alkenylene, substituted and unsubstituted alkynylene, substituted and unsubstituted heteroalkylene, substituted and unsubstituted heteroalkenylene, substituted and unsubstituted heteroalkynylene, substituted and unsubstituted heterocyclylene, substituted and unsubstituted carbocyclylene, substituted and unsubstituted arylene, substituted and unsubstitute
- Embodiment 16 The method or use of Embodiment 14, wherein L2 comprises at least one instance selected from the group consisting of substituted or unsubstituted Ci-6 alkylene, substituted or unsubstituted C2-6 alkenylene, substituted or unsubstituted C2-6 alkynylene, substituted or unsubstituted heteroCi-6alkylene, substituted or unsubstituted heteroC2-6alkenylene, substituted or unsubstituted heteroC2-6alkynylene, substituted or unsubstituted C3-6carbocyclylene, substituted or unsubstituted 3-6 membered heterocyclylene, substituted or unsubstituted phenylene, and substituted or unsubstituted 5- to 6-membered heteroarylene.
- L2 comprises at least one instance selected from the group consisting of substituted or unsubstituted Ci-6 alkylene, substituted or unsubstituted C2-6 alkenylene,
- Embodiment 17 The method or use of Embodiment 14, wherein L2 comprises at least one instance selected from the group consisting of substituted or unsubstituted methylene, ethylene, n-propylene, n-butylene, n-pentylene, n-hexylene, -
- Embodiment 18 The method or use of Embodiment 14, wherein at least one chain atom of the hydrocarbon chain of L2 is independently replaced with a 6-membered heterocyclyl group with 1-3 ring heteroatoms selected from the group consisting of nitrogen and oxygen; preferably, at least one chain atom of the hydrocarbon chain of L2 is independently replaced with piperidine, piperazine or morpholine; preferably, at least one chain atom of the hydrocarbon chain of L2 is independently replaced with an optionally substituted phenyl group.
- Embodiment 19 Embodiment 19.
- Embodiment 14 wherein L2 is an unsubstituted hydrocarbon chain, optionally wherein one or more chain atoms of the hydrocarbon chain are independently replaced with -NR a1 -, and each instance of R al is independently hydrogen, substituted or unsubstituted Ci-e alkyl or a nitrogen protecting group, or optionally two instances of R al are taken together with their intervening atoms to form a substituted or unsubstituted heterocyclic or substituted or unsubstituted heteroaryl ring.
- Embodiment 20 The method or use of Embodiment 19, wherein at least one instance of R al is hydrogen, substituted or unsubstituted Ci-6 alkyl (e.g., substituted or unsubstituted methyl or ethyl), or a nitrogen protecting group (e.g., benzyl, t-butyl carbonate, benzyl carbamate, 9-fluorenylmethyl carbonate, trifluoroacetyl, triphenylmethyl, acetyl or p-toluenesulfonamide).
- a nitrogen protecting group e.g., benzyl, t-butyl carbonate, benzyl carbamate, 9-fluorenylmethyl carbonate, trifluoroacetyl, triphenylmethyl, acetyl or p-toluenesulfonamide.
- Embodiment 21 The method or use of Embodiment 11, wherein Li i iss wherein g is 1, 2, 3, 4, 5, or 6.
- Embodiment 22 The method or use of Embodiment 11, wherein L2 includes the moiety
- Embodiment 23 The method or use of Embodiment 11, wherein L2 is selected from the group consisting of
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Treating Waste Gases (AREA)
Abstract
La présente invention concerne des composés comprenant une fraction de liaison à l'ubiquitine ligase E3 et une fraction de liaison à la protéine alpha-synucléine, destinés à être utilisés dans le traitement de maladies neurodégénératives, en particulier de synucléinopathies.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB2021/054167 WO2022238737A1 (fr) | 2021-05-14 | 2021-05-14 | Composés pour la dégradation d'agrégats d'alpha-synucléine et leurs utilisations |
Publications (1)
Publication Number | Publication Date |
---|---|
EP4337259A1 true EP4337259A1 (fr) | 2024-03-20 |
Family
ID=76034924
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21726997.6A Pending EP4337259A1 (fr) | 2021-05-14 | 2021-05-14 | Composés pour la dégradation d'agrégats d'alpha-synucléine et leurs utilisations |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP4337259A1 (fr) |
JP (1) | JP2024517340A (fr) |
KR (1) | KR20240008335A (fr) |
CN (1) | CN117377496A (fr) |
AU (1) | AU2021444937A1 (fr) |
CA (1) | CA3218573A1 (fr) |
TW (1) | TW202304516A (fr) |
WO (1) | WO2022238737A1 (fr) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10300155B2 (en) * | 2015-12-31 | 2019-05-28 | Washington University | Alpha-synuclein ligands |
WO2018102067A2 (fr) | 2016-11-01 | 2018-06-07 | Arvinas, Inc. | Protacs ciblant la protéine tau et méthodes d'utilisation associées |
ES2965049T3 (es) | 2017-07-12 | 2024-04-10 | Dana Farber Cancer Inst Inc | Compuestos para la degradación de la proteína tau |
AU2019265346B2 (en) | 2018-05-09 | 2022-06-16 | Aprinoia Therapeutics Limited | Heteroaryl compounds and uses thereof |
WO2020041331A1 (fr) * | 2018-08-20 | 2020-02-27 | Arvinas Operations, Inc. | Composé chimère ciblant la protéolyse (protac) ayant une activité de liaison à l'ubiquitine ligase e3 et ciblant une protéine alpha-synucléine pour le traitement de maladies neurodégénératives |
-
2021
- 2021-05-14 WO PCT/IB2021/054167 patent/WO2022238737A1/fr active Application Filing
- 2021-05-14 EP EP21726997.6A patent/EP4337259A1/fr active Pending
- 2021-05-14 KR KR1020237042637A patent/KR20240008335A/ko active Search and Examination
- 2021-05-14 JP JP2023570190A patent/JP2024517340A/ja active Pending
- 2021-05-14 CN CN202180098221.5A patent/CN117377496A/zh active Pending
- 2021-05-14 CA CA3218573A patent/CA3218573A1/fr active Pending
- 2021-05-14 AU AU2021444937A patent/AU2021444937A1/en active Pending
-
2022
- 2022-05-13 TW TW111118050A patent/TW202304516A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
AU2021444937A1 (en) | 2023-11-30 |
JP2024517340A (ja) | 2024-04-19 |
TW202304516A (zh) | 2023-02-01 |
WO2022238737A1 (fr) | 2022-11-17 |
KR20240008335A (ko) | 2024-01-18 |
CN117377496A (zh) | 2024-01-09 |
CA3218573A1 (fr) | 2022-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11065231B2 (en) | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides | |
AU2017222958B2 (en) | Glycosidase inhibitors | |
AU2017222964B2 (en) | Glycosidase inhibitors | |
JP6851367B2 (ja) | Irak4阻害剤、及びその応用 | |
US20080188502A1 (en) | New Compounds I | |
WO2018102751A1 (fr) | Inhibiteurs de petites molécules ire1 | |
TW202000674A (zh) | 稠合噻吩化合物 | |
KR20170083135A (ko) | 시르투인 조정제로서의 치환된 가교된 우레아 유사체 | |
US20220280650A1 (en) | Compounds for degrading alpha-synuclein aggregates and uses thereof | |
CA3167339A1 (fr) | Pyrazolo-pyrimidines substituees et leurs utilisations | |
EP4337259A1 (fr) | Composés pour la dégradation d'agrégats d'alpha-synucléine et leurs utilisations | |
TW201113290A (en) | Novel fused thiazolo and oxazolo pyrimidinones | |
AU2021262281A1 (en) | 1,5-dihydro-2,4-benzodiazepine-3-one derivative and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20231213 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |